bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

HLA class I genotypes customize vaccination strategies in immune simulation to
combat COVID-19
Shouxiong Huang1,2* & Ming Tan3
1Department

of Environmental and Public Health Sciences, University of Cincinnati College of

Medicine, Cincinnati, OH 45249, USA
2Immunology

Graduate Program, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

45229, USA
3Division

of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

45229, USA

Keywords: Binding affinity, human leukocyte antigen class I, CD8+ T cells, coronavirus disease
2019 (COVID-19), custom vaccination

Page

1

*Corresponding author. E-mail address: Shouxiong.huang@uc.edu

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Abstract
Memory CD8+ T cells are associated with a better outcome in Coronavirus Disease 2019
(COVID-19) and recognized as promising vaccine targets against viral infections. This study
determined the efficacy of population-dominant and infection-relevant human leukocyte
antigens (HLA) class I proteins to present severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) peptides through calculating binding affinities and simulating CD8+ T cell
responses. As a result, HLA class I proteins distinguished or shared various viral peptides
derived from viruses. HLA class I supertypes clustered viral peptides through recognizing
anchor and preferred residues. SARS-CoV-2 peptides overlapped significantly with SARS but
minimally with common human coronaviruses. Immune simulation of CD8+ T cell activation
using predicted SARS-CoV-2 peptide antigens depended on high-affinity peptide binding,
anchor residue interaction, and synergistic presentation of HLA class I proteins in individuals.
Results demonstrated that multi-epitope vaccination, employing a strong binding affinity, viral
adjuvants, and heterozygous HLA class I genes, induced potent immune responses. Therefore,
optimal CD8+ T cell responses can be achieved and customized contingent on HLA class I
genotypes in human populations, supporting a precise vaccination strategy to combat COVID-

Page

2

19.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Introduction
Coronavirus disease 2019 (COVID-19) pandemics has raised more than 55 million cases globally
since earlier this year and remains rapid spreading with over a half-million new daily infections
worldwide1. COVID-19 is caused by the infection of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), characterized as pneumonia and lymphopenia, and develops
severe respiratory or multiple organ failure in around 5% of patients2. Recent vaccine
development mainly focused on the induction of neutralizing antibodies. Although multiple
vaccination strategies are under clinical trials3, their protection against COVID-19 in large
human populations remains unknown. Considering disappointing efficacy or insufficient
protection frequently occurred in previous anti-viral vaccine trials using large human
populations, alternative approaches to stimulate protective immunity and control infections
effectively remain urgently needed.
CD8+ T cells mediate essential immune responses against numerous intracellular viral infections
to provide durable T cell memory and protection up to many years after infections, such as in
immune defense against SARS4-6, HIV7,8, and influenza virus infections9,10. Clinical trials of antiviral vaccines frequently led to disappointing results with weak CD8+ T cell responses7,8,11,
supporting the importance of anti-viral CD8+ T cell responses in different human populations.
Indeed, viral-specific CD8+ T cells are essential for viral clearance and long-term protection
against HIV12, Ebola13, hepatitis B viruses14, and cytomegalovirus15, despite the critical role of
neutralizing antibodies for blocking viral entry to human cells6,16-18. In COVID-19, it is likely
important to stimulate both neutralizing antibodies and CD8+ T cell responses to achieve full
protection, as in viral vaccination trials against SARS19 and influenza virus6,20. SARS-CoV-2
infections induce a dramatic reduction of CD8+ T cells associated with severe21,22 and elderly
patients23. Multiple recent reports strongly support that viral-specific and memory CD8+ T cell
responses are associated with milder diseases, younger patients24, and convalescent phases of
infections25,26, although HLA genotype27, differentiation kinetics28,29, and adjuvant usage30
impact the protection of CD8+ T cells subsets.
Activation of viral-specific CD8+ T cells and killing of viral-infected cells rely on antigen-

peptides as in a key-to-lock model33,34, which interacts with the T cell receptor of CD8+ T cells

Page

microenvironment31,32. A fundamental mechanism is that HLA class I proteins bind specific viral

3

presentation mediated by HLA class I proteins together with co-stimulation and cytokine

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

for activation and viral-infected cell recognition. Similar to the cell entry of SARS-CoV35, SARSCoV-2 is considered to enter lung epithelial cells and blood cells through interacting with cell
surface receptors, such as angiotensin-converting enzyme 2 (ACE2), and follow the endocytic
and cytoplasmic compartments36. Intracellular viral proteins in viral assembling and trafficking
processes can be degraded in proteasome or endosome to form antigenic peptide ligands that
further bind to HLA class I proteins through a secretory pathway or cross-presentation37,38.
Currently, computational prediction and experimental identification of peptide antigens for
CD8+ T cell activation in COVID-19 are ongoing for a purpose of “identifying vaccine
candidates”26,39-41. However, the impact of HLA class I genotypes on peptide antigen selection
and CD8+ T cell activation remains poorly understood.
To date, the HLA-A locus displays 6291 alleles that encode around 3900 proteins, and HLA-B
displays 7562 alleles that encode around 4808 proteins in humans42. It is unlikely to fully unveil
functional CD8+ T cell responses to unique peptide sets presented by each HLA class I protein.
With a wealth of structural knowledge on HLA-peptide-T cell receptor interaction32,43,
computational prediction and immune simulation as a prototypic artificial intelligent tool
become possible and essential to facilitate structural identification and functional simulation of
peptide antigen presentation for CD8+ T cell activation. This study applied affinity binding
theory to predict SARS-CoV-2 peptides for binding to different HLA class I proteins and
simulate the antigen-presentation process for CD8+ T cell activation. Results showed a
dramatically different capacity in various HLA class I proteins to bind SARS-CoV-2 peptides.
Multiple HLA class I proteins that have been indicated to associate with more severe symptoms
or weaker CD8+ T cell responses in SARS44 were demonstrated in this study for binding a less
number of SARS-CoV-2 peptides. In contrast, HLA class I proteins that have been suggested
protective or potent stimulators of CD8+ T cells in SARS45 were predicted to bind a large number
of SARS-CoV-2 peptides. Different HLA class I proteins clustered to a supertype share identical
sequences and similar binding patterns of SARS-CoV-2 peptides. Across various coronaviruses,
a large number of peptides from SARS viruses and a limited number of peptides from “common
cold”-causing human coronaviruses are identical to those of SARS-CoV-2. Further, affinitybased immune simulation provided an optimized combination of peptides dependent on HLA
class I genotypes to facilitate customizing precise vaccination strategies for individuals and

Page

4

human populations.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Results
Dominant HLA class I proteins sample various numbers of SARS-CoV-2 peptides.
To stimulate anti-COVID-19 CD8+ T cell responses, this study used NetMHCpan program to
comprehensively determine the binding affinity of SARS-CoV-2 peptides to ten dominant HLA
class I A and class I B proteins, which are frequently detected in the United States (US)46. HLA-C
alleles were not involved since HLA-C proteins mainly induce immune tolerance47. The
threshold of sufficient binding affinity was defined using a half-maximal inhibitory
concentration (IC50<500nM), in which the maximal concentration of a SARS-CoV-2 peptide is
required to competing off the binding of a probe peptide to each HLA class I protein. The spike
(S), membrane (M), nucleocapsid (N), and multiple ORF-encoded proteins (Fig. S1A) of the
SARS-CoV-2 virus are considered immunogenic and are analyzed in this study because
representative peptides of these proteins stimulate CD8+ T cells isolated from COVID-19
patients39,40. Various numbers of SARS-CoV-2 peptides were predicted with a high binding
affinity to ten dominant HLA class I A and B proteins (Fig. S1A). These ten alleles exist in 78.5%
of the US population approximately. Upon the further consideration of the earlier processes in
antigen presentation, including proteasome degradation (cutoff>5 potential cutting sites by
proteasome enzymes)48 and peptide transportation through the transporter associated with
antigen processing (TAP, cutoff IC50<1nM)49, 80% to 100% peptide ligands for HLA class I
proteins remained significant (Fig. 1A).
As a result, striking variation exists in the numbers of SARS-CoV-2 peptides sampled by
different dominant HLA class I proteins. Most of the ten dominant HLA-A and B proteins bound
high numbers of peptides derived from noted immunogenic SARS-CoV-2 proteins. A*02:01 and
A*11:01 bound the highest numbers of peptides (Fig. 1), indicating that a large human
population expressing at least one of these dominant HLA class I alleles is able to respond to
SARS-CoV-2 infection. The capacity of binding a higher number of viral peptides suggests a
potential dominancy of viral-induced CD8+ T cell responses. These potent peptide binders can
compensate with weak peptide binders and balance the overall ability of antigen presentation
for CD8+ T cell activation, if an HLA class I genotype combines both potent and weak peptide
binders in the same individual. Apparently, some SARS-CoV-2 proteins provided a lower

further normalized with the chain length of each SARS-CoV-2 protein (Fig. 1B). As a result,

Page

proteins. Thus, to estimate a critical protein source of viral peptides, peptide numbers were

5

number of peptides due to their short chain length of proteins, such as N and ORF8-encoded

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

among different SARS-CoV-2 proteins, fewer percentage of peptides from N and ORF8-encoded
proteins are presented by most HLA-A proteins. Among different HLA class I proteins, HLA-A
proteins overall displayed a higher peptide loading capacity than HLA-B proteins. For example,
HLA-A*02:01, A*11:01, and A*24:02 sampled a higher % of peptides from multiple viral
proteins, except for N and ORF8-encoded proteins (Fig. 1B). HLA-B*35:01 showed a high
peptide loading capacity than other HLA-B proteins. Although the numbers of peptide ligands
do not necessarily reflect the protection of peptide antigens in diseases, predicted peptides
binding to HLA proteins raise a critical concern that various human populations with various
HLA class I genotypes will respond differently in COVID-19 infections.
To consider whether HLA class I sequence heterogeneity selects various numbers of peptide
ligands, 1 and 2 ligand-binding domains of ten HLA class I proteins were aligned (Fig. S1B),
using a hierarchical clustering approach50. Overall resulted similarity ranged from 75% to 96%,
with the highest similarity between A*03:01 and A*11:01 (96.15%) (Fig. S1C). However, the
numbers of predicted peptides appear generally unmatched with the degree of similarity
between different HLA class I proteins. For example, A*02:01 shows 92.31% similarity to
A*03:01, but they have very different numbers of binding peptides for the same proteins (Fig.
1A). Similar non-concordance occurs between A*01:01 and A*11:01 with 93.96% sequence
similarity and between A*03:01 and A*11:01 with the highest sequence similarity of 96.15%.
These results suggest a need to exam the similarity of peptide-binding domains among HLA
class I proteins.
Dominant HLA class I proteins share limited numbers of SARS-CoV-2 peptides. To
determine the conservation of viral peptides for CD8+ T cell activation in different human
populations, we applied Venn diagrams to show the numbers of predicted identical peptides
between dominant HLA-A proteins (Fig. 2A) and HLA-B proteins (Fig. 2B). We used the spike
and ORF1ab genes, which encode longer protein sequences than others, to provide a higher
chance of overlapped peptide sampling by different HLA class I proteins. As a result, identical
peptides are infrequently shared by many HLA class I proteins despite high sequence similarity
(>90%) between HLA-A or HLA-B proteins (Fig. S1C). For some HLA proteins, vast numbers of
shared peptides were observed, for example, between A*03:01 and A*11:01 with an extremely

particular, almost 80% or 85% of peptides bound to A*03:01 also bind to A*11:01. However,

Page

of 89.56%, or between B*35:01 and B*07:02 with a lower sequence similarity of 88.46%. In

6

high sequence similarity of 96.15%, across B*40:01 and B*44:03 with a relatively low similarity

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

HLA sequence similarity is overall discordant to the numbers of shared peptides. B*08:01 and
B*07:02 (93.41% sequence similarity) shared much fewer numbers of peptides, and B*08:01
and B*40:01 (92.31% sequence similarity) shared no peptide from the S protein or only 1 out of
340 peptides from the ORF1ab-encoded proteins. Therefore, an overall high sequence similarity
does not suggest a high number of peptide overlap. As in the sequence alignment (Fig. S1B),
potential determinants for the numbers of shared peptides likely originate from hot spots with
limited numbers of residues in ligand-binding grooves. The similarity of these key residues and
pocket structures assigns HLA class I proteins to multiple supertypes51,52. Indeed, high numbers
of identical SARS-CoV-2 peptides were shared between HLA class I proteins of the same
supertypes, such as supertypes A03 (A*03:01 and A*11:01), B07 (B*35:01 and B*07:02), and
B40 (B*40:01 and B*44:03) (Fig. 2).
Further, peptide-binding motifs of HLA class I proteins interact with anchor and preferred
residues of peptide ligands to achieve high binding affinity (Fig. 3). The unique or shared anchor
residues validates the binding of predicted SARS-CoV-2 peptides to specific HLA class I proteins
or to HLA class I supertypes, respectively. Thus, the GibbsCluster program53,54 was applied to
determine the residue patterns of predicted SARS-CoV-2 peptides. As a result, SARS-CoV-2
peptides showed conserved residues at positions 2 or 3 and 9, matching the reported anchor
residues or preferred residues with corresponding HLA class I proteins (Fig. 3). HLA class I
proteins assigned to the same supertypes shared similar anchor and preferred residues, as for
supertypes B40 (B*40:01 and B*44:03), and to a less degree for B07 (B*35:01 and B*07:02)55-60.
For A*03:01 with undefined anchor and preferred residues, this study showed a similar pattern
of peptide binding to A*03:01 as to A*11:01, which display a sequence similarity of 96.15% (Fig.
1C) and belong to A03 supertype52. Therefore, predicted SARS-CoV-2 peptides form various
patterns of anchor and preferred residues, which are shared within an HLA class I supertype
(Fig. 3), as a unique conserved mechanism to implement HLA genotype-customized CD8+ T cell
activation in various human populations.
HLA class I proteins with weak peptide binding capacity incline to associate with
severe infections. Multiple HLA class I proteins have been reported to associate with more
severe diseases of viral infections. In SARS infections, B*46:01 was associated with severe cases

including A*03:01 and A*11:01, was considered as potent stimulators for CD8+ T cells against

Page

pass multiple tests61. In contrast, peptide binding to the HLA class I proteins of A03 supertype,

7

in a study using a small sample size44 and the association of B*07:03 with severe SARS could not

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

SARS45, and the potential association of B*15:02 with resistance to SARS is not statistically
significant in multiple tests61. Since individuals usually express two to four heterozygous or
homozygous HLA class I A and B paralogous proteins, the potential association of one protein
with severe diseases is likely balanced or interfered by other heterozygous HLA class I proteins
in human population studies. The numbers of predicted peptide ligands in our study are
supportive of a potential association of these HLA class I proteins with severity or protection of
infections. For potent peptide binders potentially associated with resistance or protection,
A*02:01, A*11:01, and B*15:03 sampled a large number of peptides (Fig. 4A). These results are
consistent with a common stimulator of A*11:01 for anti-SARS CD8+ T cell responses45, a
potential association of B*15:02 with the resistance to SARS61, and needs to further understand
the effector phenotypes27 and kinetics29 of A*02-mediated CD8+ T cell responses in COVID-19.
Belonging to the same supertypes (Fig. 4) and share high sequence homology (Fig. S2), A*02:02
sampled a high number of peptides as for A*02:01 (A02 supertype), and the similar was
observed for B*15:01, B*15:02, and B*15:03, although a controversy remains in their assignment
to one supertype or two supertypes52,62. Interestingly, SARS-CoV-2 peptides were predicted to be
overlapped between A*02 and B*15 proteins or between A*11 and B*15 proteins (Fig. 4B),
providing an additional possibility of identical peptides unusually shared by paralogous HLA
class I proteins. On the other side, relative weak peptide binders B*07:03 and B*46:01 in this
study were suggested potentially associated with severe SARS in some studies61 or with a small
sample size44. B*07:02 and B*07:03 alleles (B07 supertype) sampled relatively fewer numbers of
peptides in comparison to potent peptide binders such as A*02:02 or B*15:03, consistent with
its difficulty to pass multiple tests in severe SARS61 if co-expressed with strong binders.
Surprisingly, B*46:01 is predicted almost not binding to peptides from SARS-CoV-2 (Fig. 4A),
suggesting a potential weak CD8+ T cell response against COVID-19 and consistent to its
association with severe SARS infection44. A*25:01 binds a very limited number of SARS-CoV-2
peptides at low binding affinity, indicating a potential concern of weak responses in patients
with an A*25:01 allele. These results allow us to predict and prepare to overcome weak peptide
presenters in fighting human COVID-19 infections.
Overlapped HCoV and SARS-CoV-2 peptides suggests cross-reactive CD8+ T cells.
Recent tests demonstrated that non-infected healthy donors contain CD8+ T cells responding to

Moreover, cross-reactivity is more prominent and much stronger between SARS and SARS-CoV-

Page

infection in humans can generate cross-reactive CD8+ T cells against SARS-CoV-2 infections.

8

SARS-CoV-2 peptides39,40. Therefore, one can hypothesize that “common cold” coronavirus

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

240. Our predicted numbers of overlapped peptides can overall explain this cross-reactivity.
SARS and SARS-CoV-2 share various sequence similarity, such as 77.54% for S protein (Fig. S3)
and 95.37% for ORF1b-encoded proteins (Fig. S4), contributing to the overlap of 69 peptides
from spike protein and 438 peptides from ORF1b-encoded proteins between SARS with SARSCoV-2 (Fig. 5). Since CD8+ T cells exposed to “common cold” coronaviruses are potentially
reactive to SARS-CoV-2 peptides, the prediction of human coronavirus peptides contributing to
this cross-reactivity will provide bases for cross-virus protection. However, HCoV-OC43 and
SARS-CoV-2 share much lower sequence similarity at 33.06% for S protein (Fig. S3) and 62.32%
for ORF1b-encoded proteins, contributing to 44 shared peptides (5%) from ORF1b-encoded
proteins but nearly zero shared peptide from N, S, and ORF1a-encoded proteins between HCoVOC43 and SARS-CoV-2 (Fig. 5). This limited number of cross-reactive peptides from HCoV is
valuable for further functional investigations for cross protection.
Heterozygous HLA class I genotypes with high affinity peptides enhance CD8+ T
cell responses in immune simulation. To predict whether high peptide binding affinity,
peptide numbers, and HLA class I heterozygosity enhance CD8+ T cell responses, we use an
agent-based simulator, C-ImmSim, to simulate antigen presentation for CD8+ T cell activation63.
C-ImmSim mainly incorporated the impact of HLA-peptide binding, innate signaling, memory
responses, and adjuvant effect in antigen presentation and CD8+ T cell activation, particularly
differentiating the effect of heterozygosity or homozygosity of HLA genes63. First, we compared
CD8+ T cell responses to one versus ten peptides with a high binding affinity (IC50<16nM)
without involving innate or adjuvant factors. Results showed that one peptide is insufficient, but
a combination of ten peptides, stimulated CD8+ T cell responses that became saturated in
around two weeks (Fig. 6A). In this simulation, multi-epitopes stimulated more robust CD8+ T
cell responses than one epitope, possibly due to very strong total binding avidity. Second, to
more precisely test the avidity hypothesis, five peptides with the highest IC50 were compared
with the other five peptides with the lowest IC50 as loaded to the same A*02:01 protein. Results
further supported the conclusion that strong CD8+ T cell responses are more likely to be
activated by multiple peptides with a high binding affinity (low IC50) to HLA class I proteins
(Fig. 6B). Further, to determine whether heterozygous HLA-A or HLA-B proteins show an
advantage to enhance CD8+ T cell responses than homozygous A*02:01 or B*44:02 alone,

showed similar strength for CD8+ T cell activation to heterozygous HLA class I A or B proteins

Page

responses by heterozygous HLA-A or B proteins. Moreover, paralogous HLA-A and B proteins

9

results showed peptides with similar or lower binding affinity stimulated stronger CD8+ T cell

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

(Fig. 6C). Therefore, high peptide binding affinity, HLA gene heterogeneity, and paralogous
HLA-A and B proteins provide advantages to stimulate a robust CD8+ T cell response.
Heterozygous HLA class I genotypes with viral adjuvants rescue CD8+ T cell
responses in immune simulation to weak peptide binders. Although B*46:01 and
B*07:02 are potentially relevant to severe SARS44,61 and shown as weak peptide binders (Fig. 4),
we speculated that CD8+ T cell responses in the individuals expressing one of these alleles can
still be strongly stimulated by optimizing peptide immunization utilizing HLA class I
heterogeneity and viral adjuvant. Strikingly, results showed that only three predicted peptides
from multiple SARS-CoV-2 proteins bind to B*46:01 at a sufficient affinity (IC50<500nM) in
comparison to hundreds or thousands of peptides sampled by other HLA class I proteins (Fig.
4A). One can imagine that an individual with a B*46:01 allele will be challenging for inducing
CD8+ T cell activation, as this likely explains why B*46:01 allele is associated with severe SARS
in a study using a small sample size44. Thus, it is critical to determine whether other HLA-A or B
alleles in the same individuals facilitate overcoming this weakness. For example, HLA-A*02:07
and HLA-B*46:01 haplotype is present in around 3.34% of Asian pacific population64. Whether
the peptides presented by HLA-A*02:07 can rescue or enhance CD8+ T cell responses mediated
by the weak peptide binder B*46:01 is critical for inducing anti-COVID-19 immunity in this
human population. By applying one additional peptide that is presented by a paralogous
A*02:07 or by a heterozygous B*07:02 protein, results supported both strategies of antigen
presentation overcame the disadvantage of B*46:01 protein for CD8+ T cell activation (Fig. 4A).
Furthermore, the application of adjuvants such as an attenuated viral strain will help provide a
cytokine environment mediated by innate cells and CD4+ T cells to facilitate the activation of
peptide-specific CD8+ T cells (Fig. 7B and 7C). In this immune simulation, the viral adjuvant
enhanced the proliferation of peptide-specific memory CD8+ T cells and balanced the
production of IFN and inhibitory cytokines with extended kinetics. Therefore, a precise
vaccination strategy considering potent peptide binders, heterozygous and paralogous
advantages of HLA class I alleles, multi-epitopes of peptide antigens, and a viral adjuvant will
induce strong anti-viral CD8+ T cell responses as tailored to individual and populational HLA

Page

10

class I genotypes.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Discussion
More than two, three, and ten thousand HLA-A and B alleles have been detected in Asian,
African, and European Americans, respectively64. The same viral proteins are expected to
induce divergent CD8+ T cell responses in different individuals or populations, demanding a
precise determination of efficacious peptide antigens presented by individual-specific HLA class
I proteins. Remarkably extensive efforts are needed to structurally profile and functionally
validate viral peptide pools for various HLA class I genotypes in ethnically diverse human
populations. Computational prediction of these tens of thousands of peptides in terms of their
binding affinity to each HLA class I proteins from tens of hundreds of HLA class I genotypes
provides highly feasible alternatives to predict candidate peptides. Further, CD8+ T cell
activation using these large numbers of combinations of predicted peptides and HLA class I
genotypes can only be possibly performed using immune simulation to provide limited
candidate strategies for further experimental and clinical tests. This study performed a
computational prediction of peptide ligands and an immune simulation of CD8+ T cell activation
using representative potent and weak peptide binders, including ten dominant HLA class I
alleles and potentially SARS-associated HLA class I alleles. Results demonstrated that multiepitope high-affinity peptides, tailored to heterozygous and paralogous HLA class I genotypes
combined with a viral adjuvant, elicits strong CD8+ T cell responses, memory CD8+ T cell
differentiation, and sustainable cytokine production.
Regardless of the degree of sequence diversity (Fig. S1C), key residues in peptide-binding motifs
define the supertypes of HLA class I proteins51,52. HLA class I proteins of the same supertypes
share peptide antigens and peptide-binding patterns, suggesting the conservation of antiCOVID-19 antigenic peptides in human populations. Briefly, large numbers of identical peptides
overlapped between A*03:01 and A*11:01 (A03 supertype), B*44:03 and B*40:01 (B40) (Fig. 2),
A*02:01 and A*02:02 (A02), B*07:02 and B*07:03 (B07), and B*15:01 and B*15:03 (B27) (Fig.
4). In these HLA class I supertypes, A*02:01 and A*02:02 shared more than 50% of identical
peptides, and three B*15 proteins shared large numbers of identical peptides (Fig. 4). Overlaps
between paralogous HLA-A*02 and B*15 proteins also occurred at a much lower degree,
implicating the presence of degenerate epitopes for CD8+ T cells65. Therefore, by defining HLA

genes of the same supertypes.

Page

class I supertypes can be applied to vaccine design for those populations expressing HLA class I

11

class I genotypes in targeted populations, similar or identical peptide antigens shared by HLA

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Peptides with high affinity and avidity stimulate robust CD8+ T cell responses and aid weak
peptide binder for T cell activation, as demonstrated by the immune simulation of antigen
presentation in this study. One of our selected peptide, “FIAGLIAIV”, presented by HLAA*02:01 has been validated for the activation of T cell from SARS patients66. Evidence was
provided with insufficiency for stimulating CD8+ T cell responses using a single peptide (Fig.
6A) or five low-affinity peptides (Fig. 6B) in a vaccination setting in comparison to strong
responses with ten peptides or five high-affinity peptides, respectively. Therefore, a high total
peptide binding affinity (or avidity) is crucial for CD8+ T cell activation in vaccination.
Heterozygosity of HLA alleles is considered as a result of balancing selection to shape
exceptional polymorphism of HLA proteins and increase host immunocompetence against
highly diverse pathogens67,68. In this study, HLA class I heterozygosity was demonstrated to
provide an advantage in presenting additional high-affinity peptides complementarily (Figs. 6
and 7). This heterozygous advantage allows the design of optimal peptide vaccination to achieve
pronounced CD8+ T cell responses. For example, HLA-B*46:01 that was predicted to bind to two
low-affinity peptides from ORF1ab-encoded proteins, in comparison to B*15:03 and B*07:02
predicted to bind 1538 and 158 peptides derived from the same SARS-CoV-2 proteins (Fig. 4),
likely supports the theory of heterozygous advantage68, if these HLA class I alleles express in an
individual. This study provided an example of immune simulation that CD8+ T cell responses in
an individual expressing a weak peptide binder HLA-B*46:01 protein can be enhanced and
rescued by the heterozygous expression of B*07:02 protein, which provided complementary
capacity in peptide presentation to enhance CD8+ T cell activation (Fig. 7A). This heterozygous
advantage has also been clinically demonstrated in individuals with heterozygous HLA class I
loci A and B for protection against human T-lymphotropic virus type-1 (HTLV-1)68,69. Thus, HLA
heterozygosity is an advantageous factor to be critically examined, particularly in the
populations or individuals with weak CD8+ T cell responses to the virus- or protein-based
vaccines, which can be rescued by providing a custom design of peptide antigens for the
presentation of heterozygous HLA class I proteins.
Dual antigen presentation mediated by paralogous HLA-A and B proteins, as existing in all HLA

B protein for a similar number of peptides (Fig. 6C). Using the weak peptide binder B*46:01 as

Page

more robust CD8+ T cell responses than the antigen presentation mediated by a single HLA-A or

12

class I haplotypes, further enhances CD8+ T cell responses. This dual antigen presentation elicits

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

an example, peptides presented by HLA-A proteins can be applied to rescue the weak CD8+ T
cell responses mediated by HLA-B*46:01 protein. For example, in clinical trials of anti-viral
vaccination, 3.34% of the Asian Pacific population co-expressing HLA-A*02:07 and the weak
peptide binder HLA-B*46:0164 can be considered to have additional peptide-based vaccination
to elicit optimal CD8+ T cell responses, as customized to this specific HLA class I genotype (Fig.
7). Moreover, viral co-vaccination or adjuvant can be applied to boost more robust or stabilized
CD8+ T cell responses for the haplotype containing B*46:01 in human populations, together
with antigen presentation mediated by either heterozygous or paralogous HLA class I A and B
proteins (Fig. 7).
In summary, precision vaccination strategies targeting CD8+ T cells can be customized on HLA
class I genotypes and peptide affinity for human populations to circumvent weak peptide
binders in T cell activation. Dependent on HLA class I genotypes from an individual or a
population, high-affinity peptides can be matched to heterozygous or paralogous HLA class I A
and B alleles together with adjuvant as customized vaccination strategies. This key-to-lock
model33,34 explains why vaccine efficacy results are usually very different between animal
experiments and human trials, because antigen-presenting molecules and peptide antigens for T
cell activation are entirely different between animals, including primates, and humans.
However, clinical trials to determine the efficacy of a vaccine is time- and labor-consuming, and
economically challenging, due to the requirement for double-blind design and the observation of
the protection under natural infection conditions in a long-term process. Computational
simulation of antigen presentation, using this study as an example, provides valuable candidate
strategies for HLA genotype-customized vaccine design using known viral protein sequences. It
is reasonable to speculate that the antigen presentation tailored to HLA genotypes of patients is
advantageous to overcome weak CD8+ T cell reactivity and facilitate achieving a high efficacy of
protection in anti-SARS-CoV-2 vaccine trials clinically.
Materials and Methods
1. Protein sequences were accessed from GenBank with accession numbers of
QHU79204.1 (spike or S protein), QLI50116.1 (membrane or M protein), QHU79211.1

coronavirus OC43 isolate include AGT51680.1 (S protein), AIX10719.1 (N protein),

Page

(ORF1a), QJQ39969 (ORF3a), QJQ27861 (ORF8), Protein sequences of human beta

13

(nucleocapsid or N protein), QJQ39966 (open reading frame 1ab or ORF1ab), QJQ27841

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

YP_009555238.1 (ORF1ab), and QBP84755.1 (ORF1a). Protein sequences of SARS
include AAP51227.1 (S protein), AAP51234.1 (N protein), QJQ39966 (ORF1ab),
QJQ27841 (ORF1a). ORF1b fragment is defined by the non-overlapped portions of
amino acid sequences between ORF1ab and ORF1a. HLA class I protein sequences for
peptide binding prediction were accessed from the website of The European Molecular
Biology Laboratory (EMBL)-European Bioinformatics Institute (EBI)
(https://www.ebi.ac.uk/ipd/imgt/hla/allele.html).
2. The alignment of protein sequences was performed using a hierarchical clustering
approach (http://multalin.toulouse.inra.fr/multalin/)50. Neutral consensus residues are
labeled in red, low consensus residues are labeled in blue, and high consensus portions
are labeled in grey as a background. Upon sequence alignment, percentages of identical
sequences are calculated and listed.
3. Affinity-based prediction of peptide ligands for HLA class I proteins. The
model NetMHCpan was chosen because this model has been widely used to predict the
binding affinity of peptide sequences with 8-11 residues to various HLA class I proteins.
NetMHCpan calculates a 50% maximal inhibitory concentration (IC50) based on the
maximal concentration of test peptides to compete off a probe peptide for binding to the
same HLA class I protein46. NetMHCpan prediction has been performed accurately in
recent antigen peptide prediction to integrate mass spectrometry-eluted ligands and
binding affinity of peptides70,71. NetMHCpan is also available for all MHC alleles to
analyze dominant and disease-associated HLA class I alleles. This study used the
NetMHCpan 4.0 program, which is a default method in the website of Immune Epitope
Database (IEDB.org) for predicting peptide ligand binding to HLA class I proteins. This
prediction was not limited to the most typical length of peptide sequence (9 amino acids)
but expanded to cover a possible length of 8 to 11 residues.
4. Proteasome degradation mainly considers the degradation mediated by immune
proteasomes, which are induced by Interferon  to generate antigenic peptides. Immune
proteasomes degrade SARS-CoV-2 proteins to polypeptides, which have a high potential

potential cutting sites at the C-termini induced by various proteasome proteases. In this

Page

digestion of enolase and casein proteins as described48 to determine the numbers of

14

to bind to MHC Class I molecules. The prediction was based on in vitro proteasomal

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

prediction, we used the Netchop v3.0 “C-term” model to remove any peptides that were
not predicted via proteasomal cleavage of the peptide’s C terminus72,73. A conserved
threshold of five was used to select peptide ligands with five or more cutting sites in
proteasome degradation to generate peptides for further canonical MHC class I antigen
processing.
5. Transportation by TAP transporters. Upon proteasome digestion, cytosol peptides
are required to be transported by peptide transporters across the endoplasmic reticulum
membrane to be loaded to the heavy chain of HLA class I proteins. It has been shown
that a high affinity of TAP transporter binding to a peptide translates into high transport
rates49. Notably, both proteasome and TAP predictions were developed using
experimental data for HLA proteins and were highly suitable for predicting viral peptide
ligands for HLA class I proteins. Interestingly, TAP ligands with high binding affinity
have an increased chance of being cleaved by the proteasome, and TAP specificity has
evolved to fit the digestion specificity of proteasomes73. Thus, the prediction of TAP
transporter binding to peptides links the processes of proteasome digestion and peptide
loading to HLA class I proteins. A TAP score estimates -log(IC50) values (log=base 10) of
peptides for binding to TAP. The cutoff of IC50 at 1 nM was used to remove peptides
with higher IC50 or lower TAP binding affinity49.
6. Alignment of peptide residues. We align short peptides using the computational
program Gibbs (http://www.cbs.dtu.dk/services/GibbsCluster/), which performs two
essential tasks simultaneously, alignment and clustering54. We used Gibbs to deconvolute binding motifs of SARS-CoV-2 peptide datasets. GibbsCluster simultaneously
clusters and aligns peptide data as a powerful tool for unsupervised motif discovery.
Results return optimal clusters with characterized sequence motifs for each cluster based
on multiple parameters, including adjustable penalties for small clusters, adjustable
penalties for overlapping groups, and a trash cluster to remove outliers. The results of
cluster peptides are shown with the frequency of specific amino acids. The sequence
motifs derived from the best solution are displayed in the form of sequence logos
generated with Seq2Logo. Colors highlight different categories of amino acids, including

class I proteins were obtained from

Page

identified anchor and preferred residues of previously defined peptide ligands for HLA

15

acidic (red), basic (blue), uncharged (green), and other residues (black). The pre-

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

(http://www.syfpeithi.de/bin/MHCServer.dll/FindYourMotif.htm) to compare with the
enriched clusters of predicted SARS-CoV-2 peptides.
7. Venn diagram was constructed using the website
(http://bioinformatics.psb.ugent.be/cgi-bin/liste/Venn/calculate_venn.htpl) for fourway and five-way Venn diagrams. Sequentially identical or overlapped peptide sequences
are defined as identical or overlapped peptides.
8. Immunity simulation was performed using C-ImmSim program
(http://150.146.2.1/C-IMMSIM/index.php?page=0)63. This prediction program
implements a Celada-Seiden model as a logical description of the mechanisms making
up humoral and cellular immune responses to a genetic antigen by incorporating known
principal factors. These core factors include MHC restriction, clonal selection by antigen
affinity, antigen presentation in cytosolic or endocytic pathways, cell-cell interactions, T
cell differentiation, and T cell memory for T cell responses. Simultaneously, C-ImmSim
considers the helper function of CD4+ T cell to antibody production and CD8+ T cell
responses. C-ImmSim has been used to predict immune response in HIV infections,
which have been validated with published clinical trials involving antiretroviral
therapies74. This study utilized C-ImmSim to predict whether peptide binding affinity,
peptide numbers, and combined HLA class I alleles impacted CD8+ T cell response to
SARS-CoV-2 peptides. Input factors included peptide sequences, HLA class I alleles,
incorporation of a viral vaccination as an adjuvant for this study. Results are shown with
the curve of CD8+ T cell proliferation and cytokine production to predict potential
effector T cell responses and memory T cell differentiation stimulated by HLA class Irestricted peptides.
Acknowledgement
Thanks to the American Lung Association for funding support (IA-629987).
Author Contributions
S.H. developed research workflow, analyzed data, and wrote the manuscript. M.T. provided

Page

16

inputs on viral vaccination and manuscript writing.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure legends:
Fig. 1. Dominant HLA class I proteins sampled various numbers of SARS-CoV-2
peptides. Peptide ligands were predicted based on binding affinity to HLA class I proteins,
digestion sites for proteasome enzymes, and binding affinity to TAP transporter. The numbers of
predicted peptide ligands from immunogenic SARS-CoV-2 proteins are listed for ten dominant
HLA class I proteins (A). % of the numbers of predicted peptides over the amino acid numbers
of different SARS-CoV-2 proteins are plotted to reflect the relative frequencies of HLA class I
peptide ligands (B).
Fig. 2. Dominant HLA class I proteins shared limited numbers of SARS-CoV-2
peptides. Numbers of predicted SARS-CoV-2 peptide ligands are shown for HLA-A proteins
(A) and HLA-B proteins (B).
Fig. 3. Enriched residues in predicted SARS-CoV-2 peptide ligands. Anchor and
preferred residues for each HLA class I proteins are compared with enriched residues from
predicted SARS-CoV-2 peptide ligands. Peptide ligands from the spike and ORF1ab-encoded
proteins are shown for HLA-A proteins (A) and HLA-B proteins (B).
Fig. 4. HLA class I proteins with weak peptide binding capacity inclined to
associate with severe infections. Peptide ligands from immunogenic SARS-CoV-2 proteins
were predicted for HLA class I proteins that were indicated relevant or irrelevant to the severity
or protection of SARS. The numbers of predicted peptide ligands are listed for different
dominant HLA class I proteins (A). Venn diagrams show the numbers of predicted peptide
ligands from the spike and ORF1ab-encoded proteins for HLA class I proteins (B). White and
yellow numbers are for overlaps by two and multiple HLA class I proteins, respectively.
Fig. 5. Overlapped peptides between SARS-CoV-2 and other coronaviruses. A. Venn
diagrams show the numbers of identical predicted peptides shared between SARS-CoV-2 and
other coronaviruses for HLA class I proteins. Large numbers show the overlaps between SARSCoV-2 and other coronaviruses (white). Numbers of identical peptides loaded to both HLA-A

Page

other coronaviruses are listed. Bold % is for overlaps between SARS-CoV-2 and HCoV-OC43.

17

and HLA-B proteins are shown in yellow. B. % of identical peptides between SARS-CoV-2 and

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. 6. Heterozygous HLA class I genotypes with high affinity peptides enhance
CD8+ T cell responses in immune simulation. Simulations of antigen presentation are
compared with one and ten peptide ligands for A*02:01 protein (A). Simulations of antigen
presentation are compared between the high and low binding affinity of five peptide ligands for
A*02:01 protein (B). Simulations of antigen presentation are compared between homozygous
(i) and heterozygous (ii) HLA-A proteins, homozygous (iii) and heterozygous (iv) HLA-B
proteins, and with paralogous HLA-A and B proteins (vi) (C).
Fig. 7. Heterozygous HLA class I genotypes with viral adjuvants rescue CD8+ T cell
responses in immune simulation to weak peptide binders. Simulations of antigen
presentation used B*46:01 only, mixed HLA-A and B*46:01, and heterozygous HLA-B alleles
with B*46:01 (A). Simulations of antigen presentation used viral adjuvant and peptide ligands
for both HLA-A and B*46:01 proteins (B). Simulations of antigen presentation used viral

Page

18

adjuvant and peptide ligands for heterozygous HLA-B proteins with B*46:01 (C).

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

References

Page

Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time.
Lancet Infect Dis 20, 533-534, doi:10.1016/S1473-3099(20)30120-1 (2020).
2 Cao, X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 20, 269270, doi:10.1038/s41577-020-0308-3 (2020).
3 Thanh Le, T. et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov 19, 305-306,
doi:10.1038/d41573-020-00073-5 (2020).
4 Channappanavar, R., Zhao, J. & Perlman, S. T cell-mediated immune response to respiratory
coronaviruses. Immunologic research 59, 118-128, doi:10.1007/s12026-014-8534-z (2014).
5 Ng, O. W. et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years postinfection. Vaccine 34, 2008-2014, doi:10.1016/j.vaccine.2016.02.063 (2016).
6 Huang, S., He, Q. & Zhou, L. T cell responses in respiratory viral infections and chronic obstructive
pulmonary disease. Chin Med J (Engl) 133, In press (2020).
7 Collins, D. R., Gaiha, G. D. & Walker, B. D. CD8(+) T cells in HIV control, cure and prevention. Nat
Rev Immunol 20, 471-482, doi:10.1038/s41577-020-0274-9 (2020).
8 Watkins, D. I. The hope for an HIV vaccine based on induction of CD8+ T lymphocytes--a review.
Mem Inst Oswaldo Cruz 103, 119-129, doi:10.1590/s0074-02762008000200001 (2008).
9 Mullbacher, A., Lobigs, M., Alsharifi, M. & Regner, M. Cytotoxic T-cell immunity as a target for
influenza vaccines. Lancet Infect Dis 6, 255-256, doi:10.1016/S1473-3099(06)70443-1 (2006).
10 Wang, Z. F. et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms
dominated by CD8(+) T cells. Nat Commun 6, doi:ARTN 6833
10.1038/ncomms7833 (2015).
11 Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously
vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028,
doi:10.1016/S0140-6736(13)60177-4 (2013).
12 Fong, Y. Y. et al. Modification of the Association Between T-Cell Immune Responses and Human
Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN
505 Trial. Journal of Infectious Diseases 217, 1280-1288, doi:10.1093/infdis/jiy008 (2018).
13 Menicucci, A. R., Sureshchandra, S., Marzi, A., Feldmann, H. & Messaoudi, I. Transcriptomic analysis
reveals a previously unknown role for CD8(+) T-cells in rVSV-EBOV mediated protection. Scientific
reports 7, 919, doi:10.1038/s41598-017-01032-8 (2017).
14 Boni, C. et al. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell
Responses in Patients With Chronic Hepatitis. Gastroenterology 157, 227-+,
doi:10.1053/j.gastro.2019.03.044 (2019).
15 Klenerman, P. & Oxenius, A. T cell responses to cytomegalovirus. Nat Rev Immunol 16, 367-377,
doi:10.1038/nri.2016.38 (2016).
16 Rouphael, N. G. et al. DNA priming and gp120 boosting induces HIV-specific antibodies in a
randomized clinical trial. J Clin Invest 129, 4769-4785, doi:10.1172/JCI128699 (2019).
17 Xia, M. et al. Bioengineered Norovirus S-60 Nanoparticles as a Multifunctional Vaccine Platform.
ACS Nano 12, 10665-10682, doi:10.1021/acsnano.8b02776 (2018).
18 Tan, M. & Jiang, X. Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile
Platforms for Antigen Presentation and Vaccine Development. Pharmaceutics 11, doi:ARTN 472
10.3390/pharmaceutics11090472 (2019).
19 Martin, J. E. et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses
in healthy adults in a Phase I clinical trial. Vaccine 26, 6338-6343,
doi:10.1016/j.vaccine.2008.09.026 (2008).
20 Wong, S. S. & Webby, R. J. Traditional and new influenza vaccines. Clin Microbiol Rev 26, 476-492,
doi:10.1128/CMR.00097-12 (2013).
21 Diao, B. et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease
2019 (COVID-19). Front Immunol 11, doi:ARTN 827 10.3389/fimmu.2020.00827 (2020).
22 Qin, C. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin
Infect Dis, doi:10.1093/cid/ciaa248 (2020).
23 Riou, J., Hauser, A., Counotte, M. J. & Althaus, C. L. Adjusted age-specific case fatality ratio during
the COVID-19 epidemic in Hubei, China, January and February 2020. medRxiv,
2020.2003.2004.20031104, doi:10.1101/2020.03.04.20031104 (2020).

19

1

Page

24 Rydyznski Moderbacher, C. et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute
COVID-19 and Associations with Age and Disease Severity. Cell, doi:10.1016/j.cell.2020.09.038
(2020).
25 Peng, Y. et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK
convalescent individuals following COVID-19. Nat Immunol 21, 1336-1345, doi:10.1038/s41590-0200782-6 (2020).
26 Ni, L. et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19
Convalescent Individuals. Immunity 52, 971-977 e973, doi:10.1016/j.immuni.2020.04.023 (2020).
27 Habel, J. R. et al. Suboptimal SARS-CoV-2-specific CD8(+) T cell response associated with the
prominent HLA-A*02:01 phenotype. Proc Natl Acad Sci U S A 117, 24384-24391,
doi:10.1073/pnas.2015486117 (2020).
28 Kared, H. et al. CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the
entire SARS-CoV-2 proteome and show kinetics of early differentiation. bioRxiv,
doi:10.1101/2020.10.08.330688 (2020).
29 Schultheiss, C. et al. Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID19 Patients Showed Signatures Associated with Severity of Disease. Immunity,
doi:10.1016/j.immuni.2020.06.024 (2020).
30 Marinaik, C. B. et al. Programming Multifaceted Pulmonary T Cell Immunity by Combination
Adjuvants. Cell Rep Med 1, 100095, doi:10.1016/j.xcrm.2020.100095 (2020).
31 Sharma, M. et al. Mucosal-associated invariant T cells develop an innate-like transcriptomic program
in anti-mycobacterial responses. Front Immunol, doi:10.3389/fimmu.2020.01136 (2020).
32 Huang, S. Targeting Innate-Like T Cells in Tuberculosis. Front Immunol 7, 594,
doi:10.3389/fimmu.2016.00594 (2016).
33 Borg, N. A. et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature
448, 44-49, doi:10.1038/nature05907 (2007).
34 Armstrong, K. M., Piepenbrink, K. H. & Baker, B. M. Conformational changes and flexibility in T-cell
receptor recognition of peptide-MHC complexes. Biochem J 415, 183-196, doi:10.1042/BJ20080850
(2008).
35 Millet, J. K. & Whittaker, G. R. Physiological and molecular triggers for SARS-CoV membrane fusion
and entry into host cells. Virology 517, 3-8, doi:10.1016/j.virol.2017.12.015 (2018).
36 Shang, J. et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117, 11727-11734,
doi:10.1073/pnas.2003138117 (2020).
37 Sigal, L. J. Activation of CD8 T Lymphocytes during Viral Infections. Encyclopedia of
Immunobiology, 286-290, doi:10.1016/B978-0-12-374279-7.14009-3 (2016).
38 Rosendahl Huber, S., van Beek, J., de Jonge, J., Luytjes, W. & van Baarle, D. T cell responses to viral
infections - opportunities for Peptide vaccination. Front Immunol 5, 171,
doi:10.3389/fimmu.2014.00171 (2014).
39 Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19
Disease and Unexposed Individuals. Cell, doi:10.1016/j.cell.2020.05.015 (2020).
40 Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and
uninfected controls. Nature, doi:10.1038/s41586-020-2550-z (2020).
41 Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.
Science 370, 89-94, doi:10.1126/science.abd3871 (2020).
42 Robinson, J. et al. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 43,
D423-431, doi:10.1093/nar/gku1161 (2015).
43 Rossjohn, J. et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev
Immunol 33, 169-200, doi:10.1146/annurev-immunol-032414-112334 (2015).
44 Lin, M. et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection.
BMC Med Genet 4, 9, doi:10.1186/1471-2350-4-9 (2003).
45 Sylvester-Hvid, C. et al. SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and
biochemical validation. Tissue Antigens 63, 395-400, doi:10.1111/j.0001-2815.2004.00221.x (2004).
46 Nielsen, M. et al. NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLAA and -B Locus Protein of Known Sequence. PLoS One 2, doi:ARTN e796
10.1371/journal.pone.0000796 (2007).
47 Papuchova, H., Meissner, T. B., Li, Q., Strominger, J. L. & Tilburgs, T. The Dual Role of HLA-C in
Tolerance and Immunity at the Maternal-Fetal Interface. Front Immunol 10, doi:ARTN 2730
10.3389/fimmu.2019.02730 (2019).

20

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Page

48 Tenzer, S. et al. Modeling the MHC class I pathway by combining predictions of proteasomal
cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci 62, 1025-1037,
doi:10.1007/s00018-005-4528-2 (2005).
49 Peters, B., Bulik, S., Tampe, R., Van Endert, P. M. & Holzhutter, H. G. Identifying MHC class I
epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol 171, 1741-1749,
doi:10.4049/jimmunol.171.4.1741 (2003).
50 Corpet, F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16, 1088110890, doi:10.1093/nar/16.22.10881 (1988).
51 Sette, A. & Sidney, J. Nine major HLA class I supertypes account for the vast preponderance of HLAA and -B polymorphism. Immunogenetics 50, 201-212, doi:10.1007/s002510050594 (1999).
52 Sidney, J., Peters, B., Frahm, N., Brander, C. & Sette, A. HLA class I supertypes: a revised and
updated classification. BMC Immunol 9, 1, doi:10.1186/1471-2172-9-1 (2008).
53 Andreatta, M., Lund, O. & Nielsen, M. Simultaneous alignment and clustering of peptide data using a
Gibbs sampling approach. Bioinformatics 29, 8-14, doi:10.1093/bioinformatics/bts621 (2013).
54 Andreatta, M., Alvarez, B. & Nielsen, M. GibbsCluster: unsupervised clustering and alignment of
peptide sequences. Nucleic Acids Res 45, W458-W463, doi:10.1093/nar/gkx248 (2017).
55 Falk, K. et al. Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules. Immunogenetics 40, 238241, doi:10.1007/BF00167086 (1994).
56 Falk, K., Rotzschke, O., Stevanovic, S., Jung, G. & Rammensee, H. G. Allele-specific motifs revealed by
sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296,
doi:10.1038/351290a0 (1991).
57 Maier, R. et al. Peptide Motifs of Hla-A3, Hla-A24, and Hla-B7 Molecules as Determined by Pool
Sequencing. Immunogenetics 40, 306-308, doi:Doi 10.1007/Bf00189978 (1994).
58 Barber, L. D. et al. Overlap in the repertoires of peptides bound in vivo by a group of related class I
HLA-B allotypes. Curr Biol 5, 179-190, doi:10.1016/s0960-9822(95)00039-x (1995).
59 Arnett, K. L., Huang, W., Valiante, N. M., Barber, L. D. & Parham, P. The Bw4/Bw6 difference
between HLA-B*0802 and HLA-B*0801 changes the peptides endogenously bound and the
stimulation of alloreactive T cells. Immunogenetics 48, 56-61, doi:10.1007/s002510050400 (1998).
60 Falk, K. et al. Peptide motifs of HLA-B35 and -B37 molecules. Immunogenetics 38, 161-162,
doi:10.1007/BF00190906 (1993).
61 Sanchez-Mazas, A. HLA studies in the context of coronavirus outbreaks. Swiss Med Wkly 150,
w20248, doi:10.4414/smw.2020.20248 (2020).
62 Doytchinova, I. A., Guan, P. P. & Flower, D. R. Identifiying human MHC supertypes using
bioinformatic methods. J Immunol 172, 4314-4323, doi:DOI 10.4049/jimmunol.172.7.4314 (2004).
63 Rapin, N., Lund, O., Bernaschi, M. & Castiglione, F. Computational Immunology Meets
Bioinformatics: The Use of Prediction Tools for Molecular Binding in the Simulation of the Immune
System. PLoS One 5, doi:ARTN e9862 10.1371/journal.pone.0009862 (2010).
64 Maiers, M., Gragert, L. & Klitz, W. High-resolution HLA alleles and haplotypes in the United States
population. Hum Immunol 68, 779-788, doi:10.1016/j.humimm.2007.04.005 (2007).
65 Doolan, D. L. et al. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple
HLA-A and HLA-B supertype alleles. Immunity 7, 97-112, doi:10.1016/s1074-7613(00)80513-0
(1997).
66 Campbell, K. M., Steiner, G., Wells, D. K., Ribas, A. & Kalbasi, A. Prediction of SARS-CoV-2 epitopes
across 9360 HLA class I alleles. bioRxiv, doi:10.1101/2020.03.30.016931 (2020).
67 Pierini, F. & Lenz, T. L. Divergent Allele Advantage at Human MHC Genes: Signatures of Past and
Ongoing Selection. Mol Biol Evol 35, 2145-2158, doi:10.1093/molbev/msy116 (2018).
68 Arora, J. et al. HLA Heterozygote Advantage against HIV-1 Is Driven by Quantitative and Qualitative
Differences in HLA Allele-Specific Peptide Presentation. Mol Biol Evol 37, 639-650,
doi:10.1093/molbev/msz249 (2020).
69 Jeffery, K. J. et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T
cell lymphotropic virus type I infection. J Immunol 165, 7278-7284,
doi:10.4049/jimmunol.165.12.7278 (2000).
70 Hoof, I. et al. NetMHCpan, a method for MHC class I binding prediction beyond humans.
Immunogenetics 61, 1-13, doi:10.1007/s00251-008-0341-z (2009).
71 Jurtz, V. et al. NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating
Eluted Ligand and Peptide Binding Affinity Data. J Immunol 199, 3360-3368,
doi:10.4049/jimmunol.1700893 (2017).

21

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Page

22

72 Kesmir, C., Nussbaum, A. K., Schild, H., Detours, V. & Brunak, S. Prediction of proteasome cleavage
motifs by neural networks. Protein Eng 15, 287-296, doi:10.1093/protein/15.4.287 (2002).
73 Nielsen, M., Lundegaard, C., Lund, O. & Kesmir, C. The role of the proteasome in generating cytotoxic
T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage.
Immunogenetics 57, 33-41, doi:10.1007/s00251-005-0781-7 (2005).
74 Mancini, E. et al. A study on the dynamics of temporary HIV treatment to assess the controversial
outcomes of clinical trials: An in-silico approach. PLoS One 13, e0200892,
doi:10.1371/journal.pone.0200892 (2018).

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. 1

A. Numbers of predicted SARS-CoV-2 peptide ligands for major HLA class I proteins
SARS-CoV-2
proteins
(# residues)

S
(1273)

M
(222)

HLA-A*01:01
HLA-A*02:01
HLA-A*03:01
HLA-A*11:01
HLA-A*24:02
HLA-B*07:02
HLA-B*08:01
HLA-B*35:01
HLA-B*40:01
HLA-B*44:03

26
91
57
107
53
17
34
67
19
16

6
41
9
23
20
6
9
14
5
4

N
ORF1ab ORF3a ORF8
(419) (6954) (275) (119)
4
8
13
19
3
18
8
13
1
3

137
656
409
616
286
158
171
334
170
119

10
48
14
22
16
6
9
14
5
9

2
8
1
1
4
4
5
3
2
0

% numbers of peptide ligands/amino acid
numbers of SARS-CoV-2 proteins

B. % numbers of predicted peptide ligands for HLA class I proteins over the numbers of
amino acid sequence for SARS-CoV-2 proteins
20
B*07:02
A*01:01
B*08:01
A*02:01
A*03:01
B*35:01
15
A*11:01
B*40:01
A*24:02
B*44:03
10
5
0

20
15
10

S

M

N
ORF1ab
SARS-CoV-2 proteins

ORF3a

ORF8

S
M
N
ORF1ab
ORF3a
ORF8

5
0

A*01:01 A*02:01 A*03:01 A*11:01 A*24:02 B*07:02 B*08:01 B*35:01 B*40:01 B*44:03
HLA class I proteins

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. 2
A. Overlaps of predicted SARS-CoV-2 peptide ligands for HLA-A proteins
1:
01
A

1

22

24
A*

0

2
:0

2
:0

24
A*

0 1
0
0
78
9 0
0
1
0
0 0 7
0
0 0
0 5 317
0 0 0
4
264 0
274
1
1:0
1
*
A

116

ORF1abencoded
proteins

4

2:0

A03
sup
erty
pe

*0

2

A03
sup
erty
pe

0

620

A*03:01

A

1

0 0
0
0
4 0
0
0 8
0
0
0
1
0
0 0
0 1
46
0 1 0
0
50
0
54
1
1:0
1
*
A

21

Spike
protein

88

0

A*0

2:0

A*03:01

*0

1:
01

A*0

3

:0

B40 supertyp
e

B*35:01

8:0
1
148
11 0 0
4
112
0
0
0
1 0
7 295
0 27
0
0
0
0
0 0
0 0
1
0 0 0
1
81 38
129
1
0:0
4
*
B

B07 supertype

B*0

44

B40 supertyp
e

ORF1abencoded
proteins

B*

3

:0

44

B*

1
31
0
1
11
0 0 1
0 1
61
0 00
4
Spike
0
0 0 0
protein 0
0 0
0 0
0
0 0 0
0
11
5
14
1
0:0
4
*
B

B07 supertype

8:0

B0
7s
B* up
07 ert
:0 yp
e
2

B*0

B*35:01

B0
7s
B up
*0 e
7: rty
02 pe

B. Overlaps of predicted SARS-CoV-2 peptide ligands for HLA-B proteins

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. 3

A. Enriched residues in predicted SARS-CoV-2 peptide ligands for HLA-A proteins
A*01:01
123456789
TD
L Y
SE

A*02:01
123456789
L
V
V
M
L

# residues 1 2 3 4 5 6 7 8 9

123456789

# residues
anchor
preferred
residues

A03 supertype
A*11:01
A*03:01
123456789 123456789
VM
L K
IL
I R
FF
Y
YY
V
I
F
A

A*24:02
123456789
Y
L
F
F
I

Spike
protein
123456789

123456789

123456789

ORF1abencoded
proteins

B. Enriched residues in predicted SARS-CoV-2 peptide ligands for HLA-B proteins

B07 supertype
B*07:02
# residues 1 2 3 4 5 6 7 8 9
anchor P
L
preferred
residues

B*08:01
123456789
L
LK K
R

B07 supertype
B*35:01
123456789
P
Y
F
M
L
I

B40 supertype
B*40:01
B*44:02
123456789 123456789
E
Y
E
I L
V
F

123456789

123456789

Spike
protein

# residues 1 2 3 4 5 6 7 8 9
ORF1abencoded
proteins

123456789

123456789

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. 4

A. Numbers of predicted SARS-CoV-2 peptide ligands for HLA class I proteins

based on proteasome digestion, TAP transportation, and peptide binding affinity.
SARS-CoV-2
proteins

S
(1273)
91
HLA-A*02:01
173
HLA-A*02:02
107
HLA-A*11:01
4
HLA-A*25:01
17
HLA-B*07:02
18
HLA-B*07:03
125
HLA-B*15:01
65
HLA-B*15:02
274
HLA-B*15:03
0
HLA-B*46:01

M
(222)
41
55
23
0
6
7
31
19
47
1

N
ORF1ab ORF3a ORF8
(419) (6954) (275) (119)
8
656
48
8
12
1104
72
10
19
616
22
1
1
28
3
0
18
158
6
4
11
171
5
1
19
741
26
11
11
393
13
7
44
1538
64
29
0
2
0
0

B. % numbers of predicted peptide ligands for HLA-A proteins over the numbers of
amino acid residues from SARS-CoV-2 proteins
HLA-A &
HLA-B
HLA-A
HLA-A
e
B0
7s
7:
02 upe
rt
yp
e

0

0

B

15

0

0

0

0

0
0

B

A

*0

2:

01

e
up A*02:02 A*11:01
s
2
A
602 *2
A0
468
5:
1
01
623 4
9
0
27
24

su

p
B*07:03 B*15:01 ert
yp
e
87 B*1
15
5
1
632 :03
126
0
10 873
13
4
8
0
7

3
1

01
2:
*0

72

1

3

7

6
0

0

:02

0

94
0 7
1
0
0
0
0
0
0
0 0
0 0
1
3 8 10
0
B*
15 140 93
3
:0
1
3
5:0
1
*
B15 super B
type
pe
perty A*0
u
s
2
2:0
A0
2
388

497 25
19
47 0 4
15
0 7
536
0
64
0
0
0

2
0
0
0
0 0
3
9 55 49
B* 799 483 6
15
64
:0
1
3
5:0
1
*
B15 super B
type
5

A*11:01

B0
7s
*0
up
7:
er
02
ty
pe

ORF1abencoded
proteins rtype

67

01

0

0

A

B*07:03 B*15:01 rty
pe
B
6
0
*1
1
113 5:0
11
0
2 155 3
3
1
3
0

1

0

pe

2:

0

0

0

3

su

*0

0

15

A

1

1

*0

01

2:

*0

A

1

p
perty A
u
s
2
*02
A0

B

A*11:01

e
up A*02:02 A*11:01
s
2
A
106 *2
83
A0
5:
0
0
0
88

B

Spike
protein ype
rt

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. 5

A. Venn diagrams of overlapped SARS-CoV-2 peptide ligands for major HLA class I A and B proteins
Spike

ORF1b
Nucleocapsid
ORF1a
HLA-B
HLA-A
HLA-B
HLA-B
HLA-A
HLA-A
HLA-B
HLA-A
SARSSARSSARSSARSSARS CoV-2
SARS CoV-2
SARS CoV-2
SARS CoV-2
73 SA
SA
SA
334 SA
RS -2 178
10
RS -2 766
76
RS -2 15
RS -2 171
A
R
A
R
A
A
R
R
V
V
S
S o
S Co 401 0 197 S
S oV
S oV
0
S
S
0
0
106
223
C
31
13
C 18
C 62
0
0
0
0
0
0
0
179
0
88
309
775
17
75
15
181
11 37 18
1
0
67 29 70
19
3
26 7
0
0
0
0
0
0
0
0
0
0
0
0

3

C4

3

C4

0

B. % numbers of overlapped peptide ligands predicted from SARS-CoV-2
and other coronavirus proteins for major HLA class I A and B proteins
Ligand binding
with

Coronaviruses to
compare with
SARS-CoV-2

S

N

ORF1a

ORF1b

HLA-A*01:01,
A*02:01, A*03:01,
A*11:01, and
A*24:02
HLA-B*07:02,
B*08:01, B*35:01,
B*40:01, and
B*44:03

SARS

25.00

58.33

23.03

69.75

HCoV-OC43

0

0

0.09

4.78

SARS

27.14

61.24

25.19

73.58

HCoV-OC43

0

0

0

5.03

% overlapped SARS-CoV-2 peptides

46

0

0

0

0

0

2

46

0

0

0

0

SARSOC43 CoV-2
S- 2 651
256
R
A
0
S oV 28
14
C
0
0
245
552
O

SARSOC43 CoV-2
S- 2 1232
440
R
A
V
0
S o 1
0
C
0
0
383
997
96 0 95
O

3

C4

0

SARSOC43 CoV-2
S- 2 46
23
R
A
V
S o 0
0
0
C
0
0
25
33
0
3
3
O

0

3

C4

O

SARSOC43 CoV-2
107
RS -2 292
A
S oV 0
0
0
C
0
0
117
243
33 0 20

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. 6

10 peptides
HLA-A*02:01
IC50
FIAGLIAIV 8.6
YLQPRTFLL 4.6
Spike: FQFCNDPFL 8.9
KIADYNYKL 15.9
SIIAYTMSL 15.3

1 peptide
HLA-A*02:01

Spike
IC50
FIAGLIAIV 8.6

FLAHIQWMV
FLLPSLATV
ORF1ab: ILFTRFFYV
YLDAYNMMI
FLLNKEMYL

1.9
2.4
2.4
2.7
2.7

Anergic CD8+ T cells

# CD8+ T cells in blood (ul)

A. Immune simulation using different numbers of predicted peptide ligands for HLA-A*02:01

Days

5 peptides
HLA-A*02:01

5 peptides
HLA-A*02:01

ORF1ab:
FLAHIQWMV
FLLPSLATV
ILFTRFFYV
YLDAYNMMI
FLLNKEMYL

IC50
ORF1ab:
TILDGISQYSL 497.9
495
ALCADSIII
FVENPDILRV 493.9
493
RIQPGQTFSV
WTLMNVLTL 491.1

IC50
1.9
2.4
2.4
2.7
2.7

Anergic CD8+ T cells

# CD8+ T cells in blood (ul)

B. Immune simulation using peptides with different binding affinity to HLA-A*02:01

Days

C. Immune simulation of antigen presentation mediated by heterozygous and paralogous major

(i)

HLA-A*02:01 IC50
VVFLHVTYV 20
FELLHAPATV 21.1
MQMAYRFNGI 33.9
YIWLGFIAGL 34

(iii)

HLA-A*02:01 IC50
FELLHAPATV 21.1
YIWLGFIAGL 34
HLA-A*02:07 IC50
YLQPRTFLL 101.8
FQFCNDPFL 365.1
(ii)

HLA-B*44:02 IC50
YEQYIKWPW 21.5
SETKCTLKSF 34.4
TEKSNIIRGW 34.9
KYEQYIKWPW 48.3

HLA-A*02:01 IC50
FELLHAPATV 21.1
YIWLGFIAGL 34
(v)

HLA-B*44:02 IC50
YEQYIKWPW 21.5
SETKCTLKSF 34.4

HLA-A*02:01 IC50
FELLHAPATV 21.1
YIWLGFIAGL 34

HLA-B*07:02 IC50
LPQGFSAL 49.2
SPRRARSV 54.6

HLA-B*44:02 IC50
YEQYIKWPW 21.5
SETKCTLKSF 34.4

(iv)

(vi)

Days

Anergic CD8+ T cells

# CD8+ T cells in blood (ul)

HLA class I A and B proteins with predicted peptide ligands from the spike protein as an exmaple

doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
Fig. 7bioRxiv preprint

A. Immune simulation of antigen presentation mediated by a weak peptide binder and a

HLA-A*02:07
Spike:
IC50
YLQPRTFLL 101.8
HLA-B*46:01 IC50
FAIGLALYY 408.5

HLA-B*46:01
ORF1ab:
IC50
FAIGLALYY 408.5

HLA-B*07:02
Spike:
IC50
LPQGFSAL 49.2
HLA-B*46:01 IC50
FAIGLALYY 408.5

Days

Anergic CD8+ T cells

# CD8+ T cells in blood (ul)

heterozygous or paralogous HLA class I protein.

HLA-B*07:02
LPQGFSAL
HLA-B*46:01
FAIGLALYY

Memory CD8+ T cells
Concentration (ng/ml)

HLA-B*07:02
LPQGFSAL
HLA-B*46:01
FAIGLALYY

Anergic CD8+ T cells
# CD8+ T cells in blood (ul)

# CD8+ T cells in blood (ul)
Peptide only
With viral adjuvant

B. Immune simulation of antigen presentation with virus adjuvant and heterozygous HLA class I proteins

Days

HLA-B*46:01
FAIGLALYY

HLA-A*02:07
YLQPRTFLL
HLA-B*46:01
FAIGLALYY

Memory CD8+ T cells
Concentration (ng/ml)

HLA-A*02:07
YLQPRTFLL

Anergic CD8+ T cells
# CD8+ T cells in blood (ul)

# CD8+ T cells in blood (ul)
With viral adjuvant
Peptide only

C. Immune simulation of antigen presentation with virus adjuvant and paralogous HLA class I proteins

Days

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

1

Supplementary Information

2
3
4
5

HLA class I genotypes customize vaccination strategies in immune simulation to

6

combat COVID-19

7
8

Shouxiong Huang1,2* & Ming Tan3

9
10

1Department

of Environmental and Public Health Sciences, University of Cincinnati College of

11

Medicine, Cincinnati, OH 45249, USA

12

2Immunology

13

45229, USA

14

3Division

15

45229, USA

Graduate Program, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

of Infectious Diseases, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

16
17
18

Keywords: Binding affinity, human leukocyte antigen class I, CD8+ T cells, coronavirus disease

19

2019 (COVID-19), custom vaccination

20
21

*Corresponding author. E-mail address: Shouxiong.huang@uc.edu

22
23
24
25
26
27
28

Page

1

29

Fig. S1

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

A. Numbers of predicted SARS-CoV-2 peptides for major HLA class I proteins based on peptide binding affinity.
SARS-CoV-2
proteins
HLA-A*01:01
HLA-A*02:01
HLA-A*03:01
HLA-A*11:01
HLA-A*24:02
HLA-B*07:02
HLA-B*08:01
HLA-B*35:01
HLA-B*40:01
HLA-B*44:03

S
(1273)
28
102
63
114
54
28
36
74
19
17

M
(222)
6
59
10
25
22
7
11
15
5
4

N
ORF1ab ORF3a ORF8
(419) (6954) (275) (119)
4
146
13
2
8
818
53
13
18
481
16
1
25
716
24
1
3
288
16
4
20
189
7
4
8
194
11
5
13
363
16
3
1
186
5
2
3
129
9
0

B. Alignment of selected major HLA-A and HLA-B alleles in US populations
HLA-A0101
HLA-A0301
HLA-A1101
HLA-A0201
HLA-A2402
Consensus
HLA-A0101
HLA-A0301
HLA-A1101
HLA-A0201
HLA-A2402
Consensus
HLA-B0702
HLA-B0801
HLA-B3501
HLA-B4001
HLA-B4403
Consensus
HLA-B0702
HLA-B0801
HLA-B3501
HLA-B4001
HLA-B4403
Consensus

1
GSHSMRYFFT
GSHSMRYFFT
GSHSMRYFYT
GSHSMRYFFT
GSHSMRYFST
GSHSMRYFfT
91
GSHTIQIMYG
GSHTIQIMYG
GSHTIQIMYG
GSHTVQRMYG
GSHTLQMMFG
GSHT.Q.M%G
1
GSHSMRYFYT
GSHSMRYFDT
GSHSMRYFYT
GSHSMRYFHT
GSHSMRYFYT
GSHSMRYFyT
91
GSHTLQSMYG
GSHTLQSMYG
GSHIIQRMYG
GSHTLQRMYG
GSHIIQRMYG
GSHtlQrMYG

90
LRGYYNQSED
LRGYYNQSEA
LRGYYNQSED
LRGYYNQSEA
ALRYYNQSEA
lrgYYNQSEa
180
CDVGPDGRFL RGYRQDAYDG KDYIALNEDL RSWTAADMAA QITKRKWEAV HAAEQRRVYL EGRCVDGLRR YLENGKETLQ
CDVGSDGRFL RGYRQDAYDG KDYIALNEDL RSWTAADMAA QITKRKWEAA HEAEQLRAYL DGTCVEWLRR YLENGKETLQ
CDVGPDGRFL RGYRQDAYDG KDYIALNEDL RSWTAADMAA QITKRKWEAA HAAEQQRAYL EGRCVEWLRR YLENGKETLQ
CDVGSDWRFL RGYHQYAYDG KDYIALKEDL RSWTAADMAA QTTKHKWEAA HVAEQLRAYL EGTCVEWLRR YLENGKETLQ
CDVGSDGRFL RGYHQYAYDG KDYIALKEDL RSWTAADMAA QITKRKWEAA HVAEQQRAYL EGTCVDGLRR YLENGKETLQ
CDVGsDgRFL RGYhQyAYDG KDYIALkEDL RSWTAADMAA QiTKrKWEAa HvAEQ.RaYL #GtCV#wLRR YLENGKETLQ
90
SVSRPGRGEP RFISVGYVDD TQFVRFDSDA ASPREEPRAP WIEQEGPEYW DRNTQIYKAQ AQTDRESLRN LRGYYNQSEA
AMSRPGRGEP RFISVGYVDD TQFVRFDSDA ASPREEPRAP WIEQEGPEYW DRNTQIFKTN TQTDRESLRN LRGYYNQSEA
AMSRPGRGEP RFIAVGYVDD TQFVRFDSDA ASPRTEPRAP WIEQEGPEYW DRNTQIFKTN TQTYRESLRN LRGYYNQSEA
AMSRPGRGEP RFITVGYVDD TLFVRFDSDA TSPRKEPRAP WIEQEGPEYW DRETQISKTN TQTYRESLRN LRGYYNQSEA
AMSRPGRGEP RFITVGYVDD TLFVRFDSDA TSPRKEPRAP WIEQEGPEYW DRETQISKTN TQTYRENLRT ALRYYNQSEA
amSRPGRGEP RFI.VGYVDD TqFVRFDSDA aSPR.EPRAP WIEQEGPEYW DR#TQI.Kt# tQTyREsLRn lrgYYNQSEA
180
CDVGPDGRLL RGHDQYAYDG KDYIALNEDL RSWTAADTAA QITQRKWEAA REAEQRRAYL EGECVEWLRR YLENGKDKLE
CDVGPDGRLL RGHNQYAYDG KDYIALNEDL RSWTAADTAA QITQRKWEAA RVAEQDRAYL EGTCVEWLRR YLENGKDTLE
CDLGPDGRLL RGHDQSAYDG KDYIALNEDL SSWTAADTAA QITQRKWEAA RVAEQLRAYL EGLCVEWLRR YLENGKETLQ
CDVGPDGRLL RGHNQYAYDG KDYIALNEDL RSWTAADTAA QISQRKLEAA RVAEQLRAYL EGECVEWLRR YLENGKDKLE
CDVGPDGRLL RGYDQDAYDG KDYIALNEDL SSWTAADTAA QITQRKWEAA RVAEQLRAYL EGLCVESLRR YLENGKETLQ
CDvGPDGRLL RGh#QyAYDG KDYIALNEDL rSWTAADTAA QItQRKwEAA RvAEQlRAYL EG.CVEwLRR YLENGK#tL#
SVSRPGRGEP
SVSRPGRGEP
SVSRPGRGEP
SVSRPGRGEP
SVSRPGRGEP
SVSRPGRGEP

RFIAVGYVDD
RFIAVGYVDD
RFIAVGYVDD
RFIAVGYVDD
RFIAVGYVDD
RFIAVGYVDD

TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA

ASQKMEPRAP
ASQRMEPRAP
ASQRMEPRAP
ASQRMEPRAP
ASQRMEPRAP
ASQrMEPRAP

WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW

DQETRNMKAH
DQETRNVKAQ
DQETRNVKAQ
DGETRKVKAH
DEETGKVKAH
D.ETrkvKAh

SQTDRANLGT
SQTDRVDLGT
SQTDRVDLGT
SQTHRVDLGT
SQTDRENLRI
SQTdRv#Lgt

C. Sequence similarity of α1 and α2 domains of selected major HLA-A and HLA-B alleles in US populations
A*01:01 A*02:01 A*03:01 A*11:01 A*24:02 B*07:02 B*08:01 B*35:01 B*40:01 B*44:03
A*01:01
100
86.81
91.76
93.96
86.26
80.22
78.57
78.57
75.82
78.57
A*02:01
100
92.31
90.11
89.01
80.22
80.22
80.22
78.57
78.57
A*03:01
100
96.15
87.36
82.97
81.32
81.32
78.57
80.22
A*11:01
100
86.81
83.52
81.32
81.87
78.57
80.77
A*24:02
100
80.77
80.77
78.57
77.47
80.77
B*07:02
100
93.41
88.46
89.56
83.52
B*08:01
100
91.76
92.31
86.26
B*35:01
100
89.56
91.76
B*40:01
100
89.56
B*44:03
100
Fig. S1. Predicted SARS-CoV-2 peptide ligands only based on binding affinity to HLA class I
proteins and sequence similarity in HLA class I proteins. Numbers show predicted peptide ligands
from immunogenic SARS-CoV-2 proteins only based on binding affinity to major HLA class I proteins (A).
Alignment of α1 and α2 domains of these HLA-A and HLA-B proteins was performed using Clustal Omega
program with residues colored in grey (identical residues), red (highly diverse), and blue (less diverse) (B). %
identical residues are listed (C).

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. S2

A. Alignment of selected major HLA-A and HLA-B alleles potentially associated with SARS
HLA-A0201
HLA-A0202
HLA-A1101
HLA-A2501
HLA-B0702
HLA-B0703
HLA-B1501
HLA-B1503
HLA-B1502
HLA-B4601
Consensus
HLA-A0201
HLA-A0202
HLA-A1101
HLA-A2501
HLA-B0702
HLA-B0703
HLA-B1501
HLA-B1503
HLA-B1502
HLA-B4601
Consensus

1
GSHSMRYFFT
GSHSMRYFFT
GSHSMRYFYT
GSHSMRYFST
GSHSMRYFYT
GSHSMRYFYT
GSHSMRYFYT
GSHSMRYFYT
GSHSMRYFYT
GSHSMRYFYT
GSHSMRYFyT
91
GSHTVQRMYG
GSHTLQRMYG
GSHTIQIMYG
GSHTLQMMFG
GSHTLQSMYG
GSHTLQSMYG
GSHTLQRMYG
GSHTLQRMYG
GSHIIQRMYG
GSHTLQRMYG
GSHtlQrM%G

SVSRPGRGEP
SVSRPGRGEP
SVSRPGRGEP
SVSRPGRGEP
SVSRPGRGEP
SVSRPGRGEP
AMSRPGRGEP
AMSRPGRGEP
AMSRPGRGEP
AMSRPGRGEP
svSRPGRGEP

RFIAVGYVDD
RFIAVGYVDD
RFIAVGYVDD
RFIAVGYVDD
RFISVGYVDD
RFISVGYVDD
RFIAVGYVDD
RFISVGYVDD
RFIAVGYVDD
RFIAVGYVDD
RFIaVGYVDD

TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA
TQFVRFDSDA

ASQRMEPRAP
ASRRMEPRAP
ASQRMEPRAP
ASQRMEPRAP
ASPREEPRAP
ASPREEPRAP
ASPRMAPRAP
ASPREEPRAP
ASPRMAPRAP
ASPRMAPRAP
ASpRmePRAP

WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW
WIEQEGPEYW

DGETRKVKAH
DGETRKVKAH
DQETRNVKAQ
DEETGKVKAH
DRNTQIYKAQ
DRNTQIYKTN
DRETQISKTN
DRETQISKTN
DRNTQISKTN
DRETQKYKRQ
Dr#Tq..Ka.

SQTHRVDLGT
SQTHRVDLGT
SQTDRVDLGT
SQTDRENLRI
AQTDRESLRN
TQTDRESLRN
TQTYRESLRN
TQTYRESLRN
TQTYRESLRN
AQTDRVSLRN
.QTdResLrn

CDVGSDWRFL
CDVGSDWRFL
CDVGPDGRFL
CDVGSDGRFL
CDVGPDGRLL
CDVGPDGRLL
CDVGPDGRLL
CDVGPDGRLL
CDVGPDGRLL
CDVGPDGRLL
CDVGpDgRlL

RGYHQYAYDG
RGYHQYAYDG
RGYRQDAYDG
RGYHQYAYDG
RGHDQYAYDG
RGHDQYAYDG
RGHDQSAYDG
RGHDQSAYDG
RGYDQSAYDG
RGHDQSAYDG
RGydQyAYDG

KDYIALKEDL
KDYIALKEDL
KDYIALNEDL
KDYIALKEDL
KDYIALNEDL
KDYIALNEDL
KDYIALNEDL
KDYIALNEDL
KDYIALNEDL
KDYIALNEDL
KDYIALnEDL

RSWTAADMAA
RSWTAADMAA
RSWTAADMAA
RSWTAADMAA
RSWTAADTAA
RSWTAADTAA
SSWTAADTAA
SSWTAADTAA
SSWTAADTAA
SSWTAADTAA
rSWTAADtAA

QTTKHKWEAA
QTTKHKWEAA
QITKRKWEAA
QITKRKWEAA
QITQRKWEAA
QITQRKWEAA
QITQRKWEAA
QITQRKWEAA
QITQRKWEAA
QITQRKWEAA
QiTqrKWEAA

HVAEQLRAYL
HVAEQWRAYL
HAAEQQRAYL
HVAEQQRAYL
REAEQRRAYL
REAEQRRAYL
REAEQWRAYL
REAEQLRAYL
REAEQLRAYL
REAEQWRAYL
reAEQ.RAYL

EGTCVEWLRR
EGTCVEWLRR
EGRCVEWLRR
EGTCVDGLRR
EGECVEWLRR
EGECVEWLRR
EGLCVEWLRR
EGLCVEWLRR
EGLCVEWLRR
EGLCVEWLRR
EG.CV#wLRR

90
LRGYYNQSEA
LRGYYNQSEA
LRGYYNQSED
ALRYYNQSEA
LRGYYNQSEA
LRGYYNQSEA
LRGYYNQSEA
LRGYYNQSEA
LRGYYNQSEA
LRGYYNQSEA
lrgYYNQSEa
180
YLENGKETLQ
YLENGKETLQ
YLENGKETLQ
YLENGKETLQ
YLENGKDKLE
YLENGKDKLE
YLENGKETLQ
YLENGKETLQ
YLENGKETLQ
YLENGKETLQ
YLENGK#tL#

B. Sequence similarity of α1 and α2 domains of selected HLA-A and HLA-B alleles associated with SARS
A*02:01 A*02:02 A*11:01 A*25:01 B*07:02 B*07:03 B*15:01 B*15:02 B*15:03 B*46:01
A*02:01
A*02:02
A*11:01
A*25:01
B*07:02
B*07:03
B*15:01
B*15:02
B*15:03
B*46:01

100

98.35
100

90.11
89.56
100

89.01
89.01
86.81
100

80.22
80.77
83.52
80.77
100

79.67
80.22
82.42
80.22
98.35
100

80.77
81.87
82.97
80.22
89.56
91.21
100

80.77
80.22
82.97
79.12
88.46
90.11
97.25
100

80.77
80.77
82.42
79.67
91.21
92.86
97.8
96.15
100

81.87
82.97
84.62
80.77
90.66
89.56
96.15
93.41
93.96
100

Fig. S2. Alignment and sequence identity of HLA class I proteins relevant or irrelevant to SARS
infections. A. alignment of α1 and α2 domains for HLA class I proteins that were indicated relevant or irrelevant to the severity or protection of SARS. Residues are colored in grey (identical residues), red (highly
diverse), and blue (less diverse). B. % identical residues are listed.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
Fig. S3
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

A. Sequence similarlity of spike protein sequences between SARS-CoV-2, SARS, and HCoV-OC43
Spike
SARS-CoV-2
SARS-CoV-2
100
SARS
HCoV-OC43

SARS
77.54
100

HCoV-OC43
33.06
33.17
100

B. Alignment of spike protein sequences between SARS-CoV-2 and SARS
SARS-CoV-2
SARS
Consensus

1
150
MFVFLVLLPL VSSQCVNLTT RTQ--LPPAY TN--SFTRGV YYPDKVFRSS VLHSTQDLFL PFFSNVTWFH AIHVSGTNGT KRFDNPVLPF NDGVYFASTE KSNIIRGWIF GTTLDSKTQS LLIVNNATNV VIKVCEFQFC NDPFLGVYYH
MFIFLLFLTL TSGSDLDRCT TFDDVQAPNY TQHTSSMRGV YYPDEIFRSD TLYLTQDLFL PFYSNVTGFH TINHT----- --FDNPVIPF KDGIYFAATE KSNVVRGWVF GSTMNNKSQS VIIINNSTNV VIRACNFELC DNPFFAV--MF!FLllLpL tSgqdl#rcT rf#..qaPaY T#..SfmRGV YYPDe!FRSd tLhlTQDLFL PF%SNVTgFH aInhs..... ..FDNPViPF nDG!YFAaTE KSN!!RGW!F GsT$#nKsQS liI!NNaTNV VIraC#F#lC ##PFlaV...

151
300
SARS-CoV-2 KNNKSWMESE FRVYSSANNC TFEYVSQPFL MDLEGKQGNF KNLREFVFKN IDGYFKIYSK HTPINLVRDL PQGFSALEPL VDLPIGINIT RFQTLLALHR SYLTPGDSSS GWTAGAAAYY VGYLQPRTFL LKYNENGTIT DAVDCALDPL
SARS -SKPMGTQTH TMIFDNAFNC TFEYISDAFS LDVSEKSGNF KHLREFVFKN KDGFLYVYKG YQPIDVVRDL PSGFNTLKPI FKLPLGINIT NFRAILT--- AFLPAQDT-- -WGTSAAAYF VGYLKPTTFM LKYDENGTIT DAVDCSQNPL
Consensus .nnkmgm#se fr!%dnAnNC TFEY!S#aFl $DleeKqGNF KnLREFVFKN iDG%lk!Ykg hqPI#lVRDL PqGFnaLePi fdLPiGINIT rFraiLa... a%LpaqDs.. .WgagAAAY% VGYLqPrTF$ LKY#ENGTIT DAVDCaq#PL
301
450
SARS-CoV-2 SETKCTLKSF TVEKGIYQTS NFRVQPTESI VRFPNITNLC PFGEVFNATR FASVYAWNRK RISNCVADYS VLYNSASFST FKCYGVSPTK LNDLCFTNVY ADSFVIRGDE VRQIAPGQTG KIADYNYKLP DDFTGCVIAW NSNNLDSKVG
SARS AELKCSVKSF EIDKGIYQTS NFRVVPSRDV VRFPNITNLC PFGEVFNATK FPSVYAWERK RISNCVADYS VLYNSTFFST FKCYGVSATK LNDLCFSNVY ADSFVVKGDD VRQIAPGQTG VIADYNYKLP DDFMGCVLAW NTRNIDATST
Consensus aElKCslKSF e!#KGIYQTS NFRVqPsrd! VRFPNITNLC PFGEVFNATr FaSVYAW#RK RISNCVADYS VLYNSafFST FKCYGVSaTK LNDLCFsNVY ADSFV!rGD# VRQIAPGQTG kIADYNYKLP DDFmGCViAW NsrNiDaksg
451
600
SARS-CoV-2 GNYNYLYRLF RKSNLKPFER DISTEIYQAG STPCNGVEGF NCYFPLQSYG FQPTNGVGYQ PYRVVVLSFE LLHAPATVCG PKKSTNLVKN KCVNFNFNGL TGTGVLTESN KKFLPFQQFG RDIADTTDAV RDPQTLEILD ITPCSFGGVS
SARS GNYNYKYRYL RHGKLRPFER DISNVPFSPD GKPCTP-PAL NCYWPLNDYG FYTTTGIGYQ PYRVVVLSYE LLNAPATVCG PKLSTDLIKN QCVNFNFNGL TGTGVLTPSS KRFQPFQQFG RDVSDFTDSV RDPKTSEILD ISPCSFGGVS
Consensus GNYNYlYRll RhgnLrPFER DISnei%qad gkPCng.eal NCYfPL#dYG FqpTnG!GYQ PYRVVVLS%E LLnAPATVCG PKlST#L!KN qCVNFNFNGL TGTGVLTeSn KrFqPFQQFG RD!aDfTDaV RDPqTlEILD IsPCSFGGVS
601
750
SARS-CoV-2 VITPGTNTSN QVAVLYQDVN CTEVPVAIHA DQLTPTWRVY STGSNVFQTR AGCLIGAEHV NNSYECDIPI GAGICASYQT QTNSPRRARS VASQSIIAYT MSLGAENSVA YSNNSIAIPT NFTISVTTEI LPVSMTKTSV DCTMYICGDS
SARS VITPGTNASS EVAVLYQDVN CTDVSTAIHA DQLTPAWRIY STGNNVFQTQ AGCLIGAEHV DTSYECDIPI GAGICASYHT VS----LLRS TSQKSIVAYT MSLGADSSIA YSNNTIAIPT NFSISITTEV MPVSMAKTSV DCNMYICGDS
Consensus VITPGTNaSn #VAVLYQDVN CT#VptAIHA DQLTPaWR!Y STGnNVFQTr AGCLIGAEHV #nSYECDIPI GAGICASYqT qs....raRS taqqSI!AYT MSLGA#nS!A YSNNsIAIPT NFsIS!TTE! $PVSMaKTSV DCnMYICGDS
751
900
SARS-CoV-2 TECSNLLLQY GSFCTQLNRA LTGIAVEQDK NTQEVFAQVK QIYKTPPIKD FGGFNFSQIL PDPSKPSKRS FIEDLLFNKV TLADAGFIKQ YGDCLGDIAA RDLICAQKFN GLTVLPPLLT DEMIAQYTSA LLAGTITSGW TFGAGAALQI
SARS TECANLLLQY GSFCTQLNRA LSGIAAEQDR NTREVFAQVK QMYKTPTLKD FGGFNFSQIL PDPLKSTKRS FIEDLLFNKV TLADAGFMKQ YGECLGDINA RDLICAQKFN GLTVLPPLLT DDMIAAYTAA LVSGTATAGW TFGAGAALQI
Consensus TECaNLLLQY GSFCTQLNRA LsGIAaEQDr NTrEVFAQVK QiYKTPpiKD FGGFNFSQIL PDPlKpsKRS FIEDLLFNKV TLADAGFiKQ YG#CLGDIaA RDLICAQKFN GLTVLPPLLT D#MIAaYTaA LlaGTaTaGW TFGAGAALQI
901
1050
SARS-CoV-2 PFAMQMAYRF NGIGVTQNVL YENQKLIANQ FNSAIGKIQD SLSSTASALG KLQDVVNQNA QALNTLVKQL SSNFGAISSV LNDILSRLDK VEAEVQIDRL ITGRLQSLQT YVTQQLIRAA EIRASANLAA TKMSECVLGQ SKRVDFCGKG
SARS PFAMQMAYRF NGIGVTQNVL YENQKQIANQ FNKAISQIQE SLTTTSTALG KLQDVVNQNA QALNTLVKQL SSNFGAISSV LNDILSRLDK VEAEVQIDRL ITGRLQSLQT YVTQQLIRAA EIRASANLAA TKMSECVLGQ SKRVDFCGKG
Consensus PFAMQMAYRF NGIGVTQNVL YENQKqIANQ FNkAIgqIQ# SLssTasALG KLQDVVNQNA QALNTLVKQL SSNFGAISSV LNDILSRLDK VEAEVQIDRL ITGRLQSLQT YVTQQLIRAA EIRASANLAA TKMSECVLGQ SKRVDFCGKG
1051
1200
SARS-CoV-2 YHLMSFPQSA PHGVVFLHVT YVPAQEKNFT TAPAICHDGK AHFPREGVFV SNGTHWFVTQ RNFYEPQIIT TDNTFVSGNC DVVIGIVNNT VYDPLQPELD SFKEELDKYF KNHTSPDVDL GDISGINASV VNIQKEIDRL NEVAKNLNES
SARS YHLMSFPQAA PHGVVFLHVT YVPSQERNFT TAPAICHEGK AYFPREGVFV FNGTSWFITQ RNFFSPQIIT TDNTFVSGNC DVVIGIINNT VYDPLQPELD SFKEELDKYF KNHTSPDVDL GDISGINASV VNIQKEIDRL NEVAKNLNES
Consensus YHLMSFPQaA PHGVVFLHVT YVPaQErNFT TAPAICH#GK AhFPREGVFV fNGThWF!TQ RNF%ePQIIT TDNTFVSGNC DVVIGI!NNT VYDPLQPELD SFKEELDKYF KNHTSPDVDL GDISGINASV VNIQKEIDRL NEVAKNLNES
1201
1277
SARS-CoV-2 LIDLQELGKY EQYIKWPWYI WLGFIAGLIA IVMVTIMLCC MTSCCSCLKG CCSCGSCCKF DEDDSEPVLK GVKLHYT
SARS LIDLQELGKY EQYIKWPWYV WLGFIAGLIA IVMVTILLCC MTSCCSCLKG ACSCGSCCKF DEDDSEPVLK GVKLHYT
Consensus LIDLQELGKY EQYIKWPWY! WLGFIAGLIA IVMVTI$LCC MTSCCSCLKG aCSCGSCCKF DEDDSEPVLK GVKLHYT

C. Alignment of spike protein sequences between SARS-CoV-2 and HCoV-OC43

1
150
SARS-CoV-2 MFVFLVLLPL VSSQCVNLTT RTQLPPAYTN SFTRGV--YY PDKVFRSSVL HSTQDLFLPF FSNVTWFHAI HVSGTNGTKR FDNPVLPFND GVYFASTEKS NIIRGWIFGT TLDSKTQSLL IVNNATNVVI KVCEFQFCND PFLGVYYHKN
HCoV-OC43 MFLIL-LISL PMAFAVIGDL KCTSDTSYIN DVDTGVPPIS TDTVDVTNGL GTYYVLDRVY LNTTLFLNGY YPTSGSTYRN MALKGSVLLS TLWFKPPFLS DFING-IFAK VKNTKVIKDD VLYSEFPAIT IGSTFVNTSY SVVVQPRTIN
Consensus MFliL.LipL pmaqaVngdl rcqldpaYiN dfdrGV..is pDkVdrsngL gstqdLdrp% lnntlflnai hpsggngtrr mankglplnd glwFappelS #iIrG.IFak tl#sKtqkdd !lnnafna!i igceFqncnd pflgqprhiN
151
300
SARS-CoV-2 NKSWMESEFR VYSSANNCTF EYVSQPFLMD LEGKQGNFKN LREFVFKNID GYFKIYSKHT PINLVRDLPQ GFSALEPLVD LPIGINITRF QTL-LALHRS YLTPGDSSSG WTAG-AAAYY VGYLQPRTFL LKYNENGTIT DAVDCALDPL
HCoV-OC43 LDNKLQGLLE ISVCQYNMC- EYPHTICHPN LGNHRTELWH LDTGVVSCLY KRNFTYDVNA DYLYFHFYQE GGTFYAYFTD TGVVTKFLFN VYLGMALSHY YVMPLTCNSK RKDGFTLEYW VTPLTSRQYL LAFNQDGIIF NAVDCMSDFM
Consensus ndnk$#gelr !sscanNcc. EYphqichm# Lenhrg#lkn LregVfknid grnkiYdkna dinlfrdlq# GgsalapltD lg!ginilrn qtL.$ALhrs YlmPgdcnSg rkaG.aaaYw VgpLqpRq%L La%N##GiIf #AVDCalDf$
301
450
SARS-CoV-2 SETKCTLKSF TVEKGIYQTS NFRVQPTESI VRFPNITNLC PFGEVFNATR FASVYAWNRK RISNCVADYS VLYNSASFST FKCYGVSPTK LNDLCFTNVY ADSFVIRGDE VRQIAPGQTG KIADYNYKLP DDFTGCVIAW NSNNLDSKVG
HCoV-OC43 SEIKCKTQSI APPTGVYELN GYTVQPIADV YRRKPNLPNC NIEAWLNDKS VPSPLNWERK TFSNCNFNMS SLMSFIQADS FTCNNIDAAK IYGMCFSSIT IDKFAIPNGR KVDLQLGNLG YLQSFNYRID TTATSCQLYY NLPAANVSVS
Consensus SEiKCklqSi apekG!Y#ln n%rVQPiad! yRrknnlnnC nieawlNakr faSplaW#RK riSNCna#mS sLmnfaqads FkCnn!daaK ind$CFsn!t aDkFaIrndr kr#ialG#lG kiad%NYrid ddaTgCqiaw Nlnaa#skVg
451
600
SARS-CoV-2 ----GNYNYL YRLFRKSNLK PFERDISTEI YQAGSTPCNG VEGFNCYFPL QSY-----GF QPTNGVGYQP YRVVVLSFEL L--HAPATVC GP-------- ---------- ---------- ---------- ---------- ---------HCoV-OC43 RFNPSTWNKR FGFIEDSVFK PQPAGVFTNH DVVYAQHCFK APKNFCPCKL NGSLCVGSGP GKNNGIGTCP AGTNYLTCHN LCNPDPITFT GPYKCPQTKS LVGIGEHCSG LAVKSDYCGG NPCTCQPQAF LGWSADSCLQ GDKCNIFANL
Consensus ....gnwNkr %rlirdSnlK Pqead!fT#h dqagaqhCng aegnnCpckL #gs.....Gf qknNG!GtcP artnyLscen L..haPaTfc GP........ .......... .......... .......... .......... ..........
601
750
SARS-CoV-2 ---------- ------KKST NLVKNKCVNF NFNGLTGTGV LTESNKKFL- PFQQFGRDIA DTTDAVRDPQ TLEILDITPC SFGGVSVITP GTNTSNQVAV LYQDVNCTEV PVAIHADQLT PTWRVYSTGS NVFQTRAGCL IGAEHVN--N
HCoV-OC43 ILHDVNSGLT CSTDLQKANT DIILGVCVNY DLYGISGQGI FVEVNATYYN SWQNLLYDSN GNLYGFRDYI TNRTFMIRSC YSGRVSAAFH AN--SSEPAL LFRNIKCNYV FNNSLTRQLQ PI-------- NYFDSYLGCV VNAYNSTAIS
Consensus .......... ......KanT #i!lnkCVN% #lnGisGqG! ltEsNak%l. pfQ#lgrDia dnldafRDpq TnrildIrpC sfGrVSaafh an..Sn#pAl L%r#!nCneV fnaiharQLq Pi........ NyF#sraGCl !nAensn..n
751
900
SARS-CoV-2 SYECDIPIGA GICASYQTQT NSPRRARS-V ASQSIIAYTM -SLGAENSVA YSNNSIAIPT NFTISVTTEI LPVSMTKTSV DCTMYICGDS TECSNLLLQY GSFCTQLNRA LTGIAVEQDK NTQEVFAQVK Q-IYKTPPIK DFGGFNFSQI
HCoV-OC43 VQTCDLTVGS GYCVDYSKNR RSRRAITTGY RFTNFEPFTV NSVNDSLEPV GGLYEIQIPS EFTIGNMEEF IQTSSPKVTI DCAAFVCGDY AACKSQLVEY GSFCDNINAI LTEVNELLDT TQLQVANSLM NGVTLSTKLK DGVNFNVDDI
Consensus sqeCDip!Ga GiCadYqk#r rSrRaars.y afqniea%Tm .Slnaenepa ggnneIaIPs #FTIgnmeEi iqtSmpKts! DCaa%!CGDs aaCknqLl#Y GSFCd#iNaa LTe!aeeqDk nqq#Vaaqlk #.!tlspkiK DggnFNfd#I
901
1050
SARS-CoV-2 LPDP------ ---SKPSKRS FIEDLLFNKV TLADAGFIKQ YGDCLGDIAA RDLICAQKFN GLTVLPPLLT DEMIAQYTSA LLAGTITSGW TFGAGAALQI PFAMQMAYRF NGIGVTQNVL YENQKLIANQ FNSAIGKIQD SLSSTASALG
HCoV-OC43 NFSPVLGCLG SECSKASSRS AIEDLLFDKV KLSDVGFVEA YNNCTGGAEI RDLICVQSYK GIKVLPPLLS ENQISGYTLA ATSASLFPPW TAAAG----V PFYLNVQYRI NGLGVTMDVL SQNQKLIANA FNNALDAIQE GFDATNSALV
Consensus nfdP...... ...SKaSkRS aIEDLLF#KV kLaDaGF!ea Yn#ClGdaaa RDLICaQk%n GikVLPPLLs ##qIaqYTlA alaasifpgW TaaAG....! PFa$#maYRi NGiGVTq#VL s#NQKLIANa FNnAidaIQ# gldaTaSALg
1051
1200
SARS-CoV-2 KLQDVVNQNA QALNTLVKQL SSNFGAISSV LNDILSRLDK VEAEVQIDRL ITGRLQSLQT YVTQQLIRAA EIRASANLAA TKMSECVLGQ SKRVDFCGKG YHLMSFPQSA PHGVVFLHVT YVPAQEKNFT TAPAICHDG- KAHFPREGVF
HCoV-OC43 KIQAVVNANA EALNNLLQQL SNRFGAISSS LQEILSRLDA LEAEAQIDRL INGRLTALNA YVSQQLSDST LVKFSAAQAM EKVNECVKSQ SSRINFCGNG NHIISLVQNA PYGLYFIHFS YVPTKYVTAK VSPGLCIAGD RGIAPKSGYF
Consensus KiQaVVNaNA #ALNnLlqQL SnrFGAISSs L##ILSRLDa lEAEaQIDRL InGRLqaL#a YVsQQLiraa e!raSAaqAa eKmnECVlgQ SkR!#FCGnG nHiiSlpQnA PhGlyFiHfs YVPaqeknak taPaiChaG. rahaPreGyF
1201
1350
SARS-CoV-2 VSNGTHWFVT QRNFYEPQII TTDNTFVSGN CDVVIGIVNN TVYDPLQPEL DSFKEELDKY FKNHTSPDVD LGDISGINAS VVNIQKEIDR LNEVAKNLNE SLIDLQELGK YEQYIKWPWY IWLGFIAGLI AIVMVTIMLC CMTSC-CSCL
HCoV-OC43 VNVNNTWMYT GSGYYYPEPI TENNVVVMST CAVNYTKAPY VMLNTSTPNL PDFREELDQW FKNQTSVAPD LS-LDYINVT FLNLQVEMNR LQEAIKVLNQ SYINLKDIGT YEYYVKWPWY VWLLIGLAGV AMLVLLFFIC CCTGCGTSCF
Consensus VnnnnhWmyT qrn%YeP#iI Te#NtfVmgn CaVnigiann tml#plqP#L ddFrEELDqw FKNqTSpapD Lg.idgINas flNiQkEi#R L#EaaKnLN# SlI#Lq#iGk YEqY!KWPWY !WLgigaag! AilmllimiC CcTgC.cSCl
1351
1379
SARS-CoV-2 KGCCSCGSCC KFDEDDSEPV LKGVKLHYT
HCoV-OC43 K---KCGGCC DDYTGYQELV IKTSHDD
Consensus K...kCGgCC dddeddqElV iKgshdd..

Fig. S3. Alignment and sequence identity of spike protein between SARS-CoV-2 and other coronavirus. A. % sequence identity is listed. B. alignment of S protein between SARS-CoV-2 and SARS. C. alignment of S protein between SARS-CoV-2 and HCoV-OC43.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. S4

A. Sequence similarity of ORF1b-encoded protein sequences between SARS-CoV-2, SARS, and HCoV-OC43
ORF1b-encoded proteins SARS-CoV-2
SARS-CoV-2
SARS
HCoV-OC43

100

SARS

HCoV-OC43

95.37
100

62.32
62.82
100

B. Alignment of ORF1b-encoded protein sequences between SARS-CoV-2 and SARS
SARS-CoV-2
SARS
Consensus

1
150
RVCGVSAARL TPCGTGTSTD VVYRAFDIYN DKVAGFAKFL KTNCCRFQEK DEDDNLIDSY FVVKRHTFSN YQHEETIYNL LKDCPAVAKH DFFKFRIDGD MVPHISRQRL TKYTMADLVY ALRHFDEGNC DTLKEILVTY NCCDDDYFNK
RVCGVSAARL TPCGTGTSTD VVYRAFDIYN EKVAGFAKFL KTNCCRFQEK DEEGNLLDSY FVVKRHTMSN YQHEETIYNL VKDCPAVAVH DFFKFRVDGD MVPHISRQRL TKYTMADLVY ALRHFDEGNC DTLKEILVTY NCCDDDYFNK
RVCGVSAARL TPCGTGTSTD VVYRAFDIYN #KVAGFAKFL KTNCCRFQEK DE#dNLiDSY FVVKRHTmSN YQHEETIYNL lKDCPAVAkH DFFKFR!DGD MVPHISRQRL TKYTMADLVY ALRHFDEGNC DTLKEILVTY NCCDDDYFNK

SARS-CoV-2
SARS
Consensus

151
300
KDWYDFVENP DILRVYANLG ERVRQALLKT VQFCDAMRNA GIVGVLTLDN QDLNGNWYDF GDFIQTTPGS GVPVVDSYYS LLMPILTLTR ALTAESHVDT DLTKPYIKWD LLKYDFTEER LKLFDRYFKY WDQTYHPNCV NCLDDRCILH
KDWYDFVENP DILRVYANLG ERVRQSLLKT VQFCDAMRDA GIVGVLTLDN QDLNGNWYDF GDFVQVAPGC GVPIVDSYYS LLMPILTLTR ALAAESHMDA DLAKPLIKWD LLKYDFTEER LCLFDRYFKY WDQTYHPNCI NCLDDRCILH
KDWYDFVENP DILRVYANLG ERVRQaLLKT VQFCDAMR#A GIVGVLTLDN QDLNGNWYDF GDF!QtaPGc GVP!VDSYYS LLMPILTLTR ALaAESHmDa DLaKPlIKWD LLKYDFTEER LcLFDRYFKY WDQTYHPNC! NCLDDRCILH

SARS-CoV-2
SARS
Consensus

301
450
CANFNVLFST VFPLTSFGPL VRKIFVDGVP FVVSTGYHFR ELGVVHNQDV NLHSSRLSFK ELLVYAADPA MHAASGNLLL DKRTTCFSVA ALTNNVAFQT VKPGNFNKDF YDFAVSKGFF KEGSSVELKH FFFAQDGNAA ISDYDYYRYN
CANFNVLFST VFPPTSFGPL VRKIFVDGVP FVVSTGYHFR ELGVVHNQDV NLHSSRLSFK ELLVYAADPA MHAASGNLLL DKRTTCFSVA ALTNNVAFQT VKPGNFNKDF YDFAVSKGFF KEGSSVELKH FFFAQDGNAA ISDYDYYRYN
CANFNVLFST VFPlTSFGPL VRKIFVDGVP FVVSTGYHFR ELGVVHNQDV NLHSSRLSFK ELLVYAADPA MHAASGNLLL DKRTTCFSVA ALTNNVAFQT VKPGNFNKDF YDFAVSKGFF KEGSSVELKH FFFAQDGNAA ISDYDYYRYN

SARS-CoV-2
SARS
Consensus

451
600
LPTMCDIRQL LFVVEVVDKY FDCYDGGCIN ANQVIVNNLD KSAGFPFNKW GKARLYYDSM SYEDQDALFA YTKRNVIPTI TQMNLKYAIS AKNRARTVAG VSICSTMTNR QFHQKLLKSI AATRGATVVI GTSKFYGGWH NML------LPTMCDIRQL LFVVEVVDKY FDCYDGGCIN ANQVIVNNLD KSAGFPFNKW GKARLYYDSM SYEDQDALFA YTKRNVIPTI TQMNLKYAIS AKNRARTVAG VSICSTMTNR QFHQKLLKSI AATRGATVVI GTSKFYGGWH NMLKTVYSDV
LPTMCDIRQL LFVVEVVDKY FDCYDGGCIN ANQVIVNNLD KSAGFPFNKW GKARLYYDSM SYEDQDALFA YTKRNVIPTI TQMNLKYAIS AKNRARTVAG VSICSTMTNR QFHQKLLKSI AATRGATVVI GTSKFYGGWH NML.......

SARS-CoV-2
SARS
Consensus

601
750
---------- ---------- ---------- ---------- ---------- -----EMVMC GGSLYVKPGG TSSGDATTAY ANSVFNICQA VTANVNALLS TDGNKIADKY VRNLQHRLYE CLYRNRDVDT DFVNEFYAYL RKHFSMMILS
ETPHLMGWDY PKCDRAMPNM LRIMASLVLA RKHNTCCNLS HRFYRLANEC AQVLSEMVMC GGSLYVKPGG TSSGDATTAY ANSVFNICQA VTANVNALLS TDGNKIADKY VRNLQHRLYE CLYRNRDVDH EFVDEFYAYL RKHFSMMILS
.......... .......... .......... .......... .......... .....EMVMC GGSLYVKPGG TSSGDATTAY ANSVFNICQA VTANVNALLS TDGNKIADKY VRNLQHRLYE CLYRNRDVDh #FV#EFYAYL RKHFSMMILS

SARS-CoV-2
SARS
Consensus

751
900
DDAVVCFNST YASQGLVASI KNFKSVLYYQ NNVFMSEAKC WTETDLTKGP HEFCSQHTML VKQGDDYVYL PYPDPSRILG AGCFVDDIVK TDGTLMIERF VSLAIDAYPL TKHPNQEYAD VFHLYLQYIR KLHDELTGHM LDMYSVMLTN
DDAVVCYNSN YAAQGLVASI KNFKAVLYYQ NNVFMSEAKC WTETDLTKGP HEFCSQHTML VKQGDDYVYL PYPDPSRILG AGCFVDDIVK TDGTLMIERF VSLAIDAYPL TKHPNQEYAD VFHLYLQYIR KLHDELTGHM LDMYSVMLTN
DDAVVC%NSn YAaQGLVASI KNFKaVLYYQ NNVFMSEAKC WTETDLTKGP HEFCSQHTML VKQGDDYVYL PYPDPSRILG AGCFVDDIVK TDGTLMIERF VSLAIDAYPL TKHPNQEYAD VFHLYLQYIR KLHDELTGHM LDMYSVMLTN

SARS-CoV-2
SARS
Consensus

901
1050
DNTSRYWEPE FYEAMYTPHT VLQAVGACVL CNSQTSLRCG ACIRRPFLCC KCCYDHVIST SHKLVLSVNP YVCNAPGCDV TDVTQLYLGG MSYYCKSHKP PISFPLCANG QVFGLYKNTC VGSDNVTDFN AIATCDWTNA GDYILANTCT
DNTSRYWEPE FYEAMYTPHT VLQAVGACVL CNSQTSLRCG ACIRRPFLCC KCCYDHVIST SHKLVLSVNP YVCNAPGCDV TDVTQLYLGG MSYYCKSHKP PISFPLCANG QVFGLYKNTC VGSDNVTDFN AIATCDWTNA GDYILANTCT
DNTSRYWEPE FYEAMYTPHT VLQAVGACVL CNSQTSLRCG ACIRRPFLCC KCCYDHVIST SHKLVLSVNP YVCNAPGCDV TDVTQLYLGG MSYYCKSHKP PISFPLCANG QVFGLYKNTC VGSDNVTDFN AIATCDWTNA GDYILANTCT

SARS-CoV-2
SARS
Consensus

1051
1200
ERLKLFAAET LKATEETFKL SYGIATVREV LSDRELHLSW EVGKPRPPLN RNYVFTGYRV TKNSKVQIGE YTFEKGDYGD AVVYRGTTTY KLNVGDYFVL TSHTVMPLST PTLVPQEHYV RITGLYPTLN ISDEFSSNVA NYQKVGMQKY
ERLKLFAAET LKATEETFKL SYGIATVREV LSDRELHLSW EVGKPRPPLN RNYVFTGYRV TKNSKVQIGE YTFEKGDYGD AVVYRGTTTY KLNVGDYFVL TSHTVMPLSA PTLVPQEHYV RITGLYPTLN ISDEFSSNVA NYQKVGMQKY
ERLKLFAAET LKATEETFKL SYGIATVREV LSDRELHLSW EVGKPRPPLN RNYVFTGYRV TKNSKVQIGE YTFEKGDYGD AVVYRGTTTY KLNVGDYFVL TSHTVMPLSa PTLVPQEHYV RITGLYPTLN ISDEFSSNVA NYQKVGMQKY

SARS-CoV-2
SARS
Consensus

1201
1350
STLQGPPGTG KSHFAIGLAL YYPSARIVYT ACSHAAVDAL CEKALKYLPI DKCSRIIPAR ARVECFDKFK VNSTLEQYVF CTVNALPETT ADIVVFDEIS MATNYDLSVV NARLRAKHYV YIGDPAQLPA PRTLLTKGTL EPEYFNSVCR
STLQGPPGTG KSHFAIGLAL YYPSARIVYT ACSHAAVDAL CEKASKYLPI DKCSRIIPAR ARVECFDKFK VNSTLEQYVF CTVNALPETT ADIVVFDEIS MATNYDLSVV NARLRAKHYV YIGDPAQLPA PRTLLTKGTL EPEYFNSVCR
STLQGPPGTG KSHFAIGLAL YYPSARIVYT ACSHAAVDAL CEKAlKYLPI DKCSRIIPAR ARVECFDKFK VNSTLEQYVF CTVNALPETT ADIVVFDEIS MATNYDLSVV NARLRAKHYV YIGDPAQLPA PRTLLTKGTL EPEYFNSVCR

SARS-CoV-2
SARS
Consensus

1351
1500
LMKTIGPDMF LGTCRRCPAE IVDTVSALVY DNKLKAHKDK SAQCFKMFYK GVITHDVSSA INRPQIGVVR EFLTRNPAWR KAVFISPYNS QNAVASKILG LPTQTVDSSQ GSEYDYVIFT QTTETAHSCN VNRFNVAITR AKVGILCIMS
LMKTIGPDMF LGTCRRCPAE IVDTVSALVY DNKLKAHKEK SAQCFKMFYK GVITHDVSSA INRPQIGVVR EFLTRNPAWR KAVFISPYNS QNAVASKILG LPTQTVDSSQ GSEYDYVIFT QTTETAHSCN VNRFNVAITR AKIGILCIMS
LMKTIGPDMF LGTCRRCPAE IVDTVSALVY DNKLKAHK#K SAQCFKMFYK GVITHDVSSA INRPQIGVVR EFLTRNPAWR KAVFISPYNS QNAVASKILG LPTQTVDSSQ GSEYDYVIFT QTTETAHSCN VNRFNVAITR AK!GILCIMS

SARS-CoV-2
SARS
Consensus

1501
1650
DRDLYDKLQF TSLEIPRRNV ATLQAENVTG LFKDCSKVIT GLHPTQAPTH LSVDTKFKTE GLCVDIPGIP KDMTYRRLIS MMGFKMNYQV NGYPNMFITR EEAIRHVRAW IGFDVEGCHA TREAVGTNLP LQLGFSTGVN LVAVPTGYVD
DRDLYDKLQF TSLEIPRRNV ATLQAENVTG LFKDCSKIIT GLHPTQAPTH LSVDIKFKTE GLCVDIPGIP KDMTYRRLIS MMGFKMNYQV NGYPNMFITR EEAIRHVRAW IGFDVEGCHA TRDAVGTNLP LQLGFSTGVN LVAVPTGYVD
DRDLYDKLQF TSLEIPRRNV ATLQAENVTG LFKDCSK!IT GLHPTQAPTH LSVDiKFKTE GLCVDIPGIP KDMTYRRLIS MMGFKMNYQV NGYPNMFITR EEAIRHVRAW IGFDVEGCHA TR#AVGTNLP LQLGFSTGVN LVAVPTGYVD

SARS-CoV-2
SARS
Consensus

1651
1800
TPNNTDFSRV SAKPPPGDQF KHLIPLMYKG LPWNVVRIKI VQMLSDTLKN LSDRVVFVLW AHGFELTSMK YFVKIGPERT CCLCDRRATC FSTASDTYAC WHHSIGFDYV YNPFMIDVQQ WGFTGNLQSN HDLYCQVHGN AHVASCDAIM
TENNTEFTRV NAKPPPGDQF KHLIPLMYKG LPWNVVRIKI VQMLSDTLKG LSDRVVFVLW AHGFELTSMK YFVKIGPERT CCLCDKRATC FSTSSDTYAC WNHSVGFDYV YNPFMIDVQQ WGFTGNLQSN HDQHCQVHGN AHVASCDAIM
TeNNT#FsRV nAKPPPGDQF KHLIPLMYKG LPWNVVRIKI VQMLSDTLKn LSDRVVFVLW AHGFELTSMK YFVKIGPERT CCLCDrRATC FSTaSDTYAC WnHS!GFDYV YNPFMIDVQQ WGFTGNLQSN HDqhCQVHGN AHVASCDAIM

SARS-CoV-2
SARS
Consensus

1801
1950
TRCLAVHECF VKRVDWTIEY PIIGDELKIN AACRKVQHMV VKAALLADKF PVLHDIGNPK AIKCVPQADV EWKFYDAQPC SDKAYKIEEL FYSYATHSDK FTDGVCLFWN CNVDRYPANS IVCRFDTRVL SNLNLPGCDG GSLYVNKHAF
TRCLAVHECF VKRVDWSVEY PIIGDELRVN SACRKVQHMV VKSALLADKF PVLHDIGNPK AIKCVPQAEV EWKFYDAQPC SDKAYKIEEL FYSYATHHDK FTDGVCLFWN CNVDRYPANA IVCRFDTRVL SNLNLPGCDG GSLYVNKHAF
TRCLAVHECF VKRVDWs!EY PIIGDELr!N aACRKVQHMV VKaALLADKF PVLHDIGNPK AIKCVPQA#V EWKFYDAQPC SDKAYKIEEL FYSYATHhDK FTDGVCLFWN CNVDRYPANa IVCRFDTRVL SNLNLPGCDG GSLYVNKHAF

SARS-CoV-2
SARS
Consensus

1951
2100
HTPAFDKSAF VNLKQLPFFY YSDSPCESHG KQVVSDIDYV PLKSATCITR CNLGGAVCRH HANEYRLYLD AYNMMISAGF SLWVYKQFDT YNLWNTFTRL QSLENVAFNV VNKGHFDGQQ GEVPVSIINN TVYTKVDGVD VELFENKTTL
HTPAFDKSAF TNLKQLPFFY YSDSPCESHG KQVVSDIDYV PLKSATCITR CNLGGAVCRH HANEYRQYLD AYNMMISAGF SLWIYKQFDT YNLWNTFTRL QSLENVAYNV VNKGHFDGHA GEAPVSIINN AVYTKVDGID VEIFENKTTL
HTPAFDKSAF tNLKQLPFFY YSDSPCESHG KQVVSDIDYV PLKSATCITR CNLGGAVCRH HANEYRqYLD AYNMMISAGF SLW!YKQFDT YNLWNTFTRL QSLENVA%NV VNKGHFDGqa GEaPVSIINN aVYTKVDG!D VEiFENKTTL

SARS-CoV-2
SARS
Consensus

2101
2250
PVNVAFELWA KRNIKPVPEV KILNNLGVDI AANTVIWDYK RDAPAHISTI GVCSMTDIAK KPTETICAPL TVFFDGRVDG QVDLFRNARN GVLITEGSVK GLQPSVGPKQ ASLNGVTLIG EAVKTQFNYY KKVDGVVQQL PETYFTQSRN
PVNVAFELWA KRNIKPVPEI KILNNLGVDI AANTVIWDYK REAPAHVSTI GVCTMTDIAK KPTESACSSL TVLFDGRVEG QVDLFRNARN GVLITEGSVK GLTPSKGPAQ ASVNGVTLIG ESVKTQFNYF KKVDGIIQQL PETYFTQSRD
PVNVAFELWA KRNIKPVPE! KILNNLGVDI AANTVIWDYK R#APAH!STI GVCsMTDIAK KPTEsaCapL TVlFDGRV#G QVDLFRNARN GVLITEGSVK GLqPSkGPaQ ASlNGVTLIG EaVKTQFNY% KKVDG!!QQL PETYFTQSR#

SARS-CoV-2
SARS
Consensus

2251
2400
LQEFKPRSQM EIDFLELAMD EFIERYKLEG YAFEHIVYGD FSHSQLGGLH LLIGLAKRFK ESPFELEDFI PMDSTVKNYF ITDAQTGSSK CVCSVIDLLL DDFVEIIKSQ DLSVVSKVVK VTIDYTEISF MLWCKDGHVE TFYPKLQSSQ
LEDFKPRSQM ETDFLELAMD EFIQRYKLEG YAFEHIVYGD FSHGQLGGLH LMIGLAKRSQ DSPLKLEDFI PMDSTVKNYF ITDAQTGSSK CVCSVIDLLL NDFVEIIKSQ DLSVISKVVK VTIDYAEISF MLWCKDGHVE TFYPKLQASQ
L##FKPRSQM EiDFLELAMD EFI#RYKLEG YAFEHIVYGD FSHgQLGGLH L$IGLAKRfq #SPleLEDFI PMDSTVKNYF ITDAQTGSSK CVCSVIDLLL #DFVEIIKSQ DLSV!SKVVK VTIDYaEISF MLWCKDGHVE TFYPKLQaSQ

SARS-CoV-2
SARS
Consensus

2401
2550
AWQPGVAMPN LYKMQRMLLE KCDLQNYGDS ATLPKGIMMN VAKYTQLCQY LNTLTLAVPY NMRVIHFGAG SDKGVAPGTA VLRQWLPTGT LLVDSDLNDF VSDADSTLIG DCATVHTANK WDLIISDMYD PKTKNVTKEN DSKEGFFTYI
AWQPGVAMPN LYKMQRMLLE KCDLQNYGEN AVIPKGIMMN VAKYTQLCQY LNTLTLAVPY NMRVIHFGAG SDKGVAPGTA VLRQWLPTGT LLVDSDLNEF VSDADSTLIG DCATVHTANK WDLIISDMYD PRTKHVTKEN DSKEGFFTYL
AWQPGVAMPN LYKMQRMLLE KCDLQNYG#n AtiPKGIMMN VAKYTQLCQY LNTLTLAVPY NMRVIHFGAG SDKGVAPGTA VLRQWLPTGT LLVDSDLN#F VSDADSTLIG DCATVHTANK WDLIISDMYD PrTKnVTKEN DSKEGFFTYi

SARS-CoV-2
SARS
Consensus

2551
2695
CGFIQQKLAL GGSVAIKITE HSWNADLYKL MGHFAWWTAF VTNVNASSSE AFLIGCNYLG KPREQIDGYV MHANYIFWRN TNPIQLSSYS LFDMSKFPLK LRGTAVMSLK EGQINDMILS LLSKGRLIIR ENNRVVISSD VLVNN
CGFIKQKLAL GGSIAVKITE HSWNADLYKL MGHFSWWTAF VTNVNASSSE AFLIGANYLG KPKEQIDGYT MHANYIFWRK TNPIQLSSYS LFDMSKFPLK LRGTAVMSLK ENQINDMIYS LLEKGRLIIR ENNRVVVSSD ILVNN
CGFIqQKLAL GGS!A!KITE HSWNADLYKL MGHFaWWTAF VTNVNASSSE AFLIGaNYLG KPrEQIDGYt MHANYIFWRn TNPIQLSSYS LFDMSKFPLK LRGTAVMSLK EnQINDMIlS LLeKGRLIIR ENNRVV!SSD !LVNN

Fig. S4. Alignment and sequence identity of ORF1b-endoced proteins between SARS-CoV-2
and other coronaviruses. A. % sequence identity is listed. B. alignment of ORF1b-endoced proteins
between SARS-CoV-2 and SARS. C. alignment of ORF1b-endoced proteins between SARS-CoV-2 and
HCoV-OC43.

bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388983; this version posted November 18, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. S4
C. Alignment of ORF1b-encoded protein sequences between SARS-CoV-2 and SARS
SARS-CoV-2
HCoV-OC43
Consensus

1
150
RVCGVSA-AR LTPCGTGTST DVVYRAFDIY NDKVAGFAKF LKTNCCRFQE KDEDDNLIDS YFVVKRHTFS NYQHEETIYN LLKDCPAVAK HDFFKFRIDG DMVPHISRQR LTKYTMADLV YALRHFDEGN CDTLKEILVT YNCCDDDYFN
RVRGTSVDAR LVPCASGLST DVQLRAFDIY NASVAGIGLH LKVNCCRFQR VDENGDKLDQ FFVVKRTDLT IYNREMKCYE RVKDCKFVAE HDFFTFDVEG SRVPHIVRKD LTKYTMLDLC YALRHFDRND CMLLCDILSI YAGCEQSYFT
RVrGtSa.AR LtPCasGlST DVqlRAFDIY NakVAGialh LKtNCCRFQr kDE#d#liDq %FVVKRhdls nY#rEekcY# rlKDCkaVAe HDFFkFr!#G drVPHIsRqr LTKYTMaDLc YALRHFDrn# CdlLc#ILsi YacC##dYFn

SARS-CoV-2
HCoV-OC43
Consensus

151
300
KKDWYDFVEN PDILRVYANL GERVRQALLK TVQFCDAMRN AGIVGVLTLD NQDLNGNWYD FGDFIQTTPG SGVPVVDSYY SLLMPILTLT RALTAESHVD TDLTKPYIKW DLLKYDFTEE RLKLFDRYFK YWDQTYHPNC VNCLDDRCIL
KKDWYDFVEN PDIINVYKKL GPIFNRALVS ATEFADKLVE VGLVGVLTLD NQDLNGKWYD FGDYVIAAPG CGVAIADSYY SYIMPMLTMC HALDCELYVN N----AYRLF DLVQYDFTDY KLELFNKYFK HWSMPYHPNT VDCQDDRCII
KKDWYDFVEN PDIirVYanL GerfrrALlk at#FaDa$r# aGiVGVLTLD NQDLNGnWYD FGD%!qaaPG cGVa!aDSYY SliMPiLT$c rALdaElhV# n....aYrlf DLlqYDFT#e rLeLF#rYFK hWdqpYHPNc V#CqDDRCIi

SARS-CoV-2
HCoV-OC43
Consensus

301
450
HCANFNVLFS TVFPLTSFGP LVRKIFVDGV PFVVSTGYHF RELGVVHNQD VNLHSSRLSF KELLVYAADP AMHAASGNLL LDKRTTCFSV AALTNNVAFQ TVKPGNFNKD FYDFAVSKGF FKEGSSVELK HFFFAQDGNA AISDYDYYRY
HCANFNILFS MVLPNTCFGP LVRQIFVDGV PFVVSIGYHY KELGIVMNMD VDTHRYRLSL KDLLLYAADP ALHVASASAL YDLRTCCFSV AAITSGVKFQ TVKPGNFNQD FYDFVLSKGL LKEGSSVDLK HFFFTQDGNA AITDYNYYKY
HCANFN!LFS mVlPnTcFGP LVRqIFVDGV PFVVSiGYH% rELG!VhNqD V#lHrsRLSl K#LLlYAADP A$HaASanaL lDlRTcCFSV AAiTnnVaFQ TVKPGNFNqD FYDFalSKGl lKEGSSV#LK HFFFaQDGNA AIsDY#YYrY

SARS-CoV-2
HCoV-OC43
Consensus

451
600
NLPTMCDIRQ LLFVVEVVDK YFDCYDGGCI NANQVIVNNL DKSAGFPFNK WGKARLYYDS MSYEDQDALF AYTKRNVIPT ITQMNLKYAI SAKNRARTVA GVSICSTMTN RQFHQKLLKS IAATRGATVV IGTSKFYGGW HNML-----NLPTMVDIKQ LLFVLEVVYK YFEIYDGGCI PASQVIVNNY DKSAGYPFNK FGKARLYYEA LSFEEQDEIY AYTKRNVLPT LTQMNLKYAI SAKNRARTVA GVSILSTMTG RMFHQKCLKS IAATRGVPVV IGTTKFYGGW DDMLRRLIKD
NLPTMcDIrQ LLFVlEVVdK YF#cYDGGCI nAnQVIVNNl DKSAG%PFNK fGKARLYY#a $S%E#QDai% AYTKRNViPT iTQMNLKYAI SAKNRARTVA GVSIcSTMTn RqFHQKcLKS IAATRGapVV IGTsKFYGGW d#ML......

SARS-CoV-2
HCoV-OC43
Consensus

601
750
---------- ---------- ---------- ---------- ---------- ------EMVM CGGSLYVKPG GTSSGDATTA YANSVFNICQ AVTANVNALL STDGNKIADK YVRNLQHRLY ECLYRNRDVD TDFVNEFYAY LRKHFSMMIL
VDNPVLMGWD YPKCDRAMPN LLRIVSSLVL ARKHETCCSQ SDRFYRLANE CAQVLSEIVM CGGCYYVKPG GTSSGDATTA FANSVFNICQ AVSANVCALM SCNGNKIEDL SIRALQKRLY SHVYRSDKVD STFVTEYYEF LNKHFSMMIL
.......... .......... .......... .......... .......... ......EiVM CGGclYVKPG GTSSGDATTA %ANSVFNICQ AVsANVnAL$ Sc#GNKIaDl s!RaLQhRLY eclYRnrdVD sdFVnE%Ya% LrKHFSMMIL

SARS-CoV-2
HCoV-OC43
Consensus

751
900
SDDAVVCFNS TYASQGLVAS IKNFKSVLYY QNNVFMSEAK CWTETDLTKG PHEFCSQHTM LVKQGDDYVY LPYPDPSRIL GAGCFVDDIV KTDGTLMIER FVSLAIDAYP LTKHPNQEYA DVFHLYLQYI RKLHDELTGH MLDMYSVMLT
SDDGVVCYNS DYASKGYIAN ISAFQQVLYY QNNVFMSESK CWVEHDINNG PHEFCSQHTM LVKMDGDDVY LPYPNPSRIL GAGCFVDDLL KTDSVLLIER FVSLAIDAYP LVYHENEEYQ KVFRVYLAYI KKLYNDLGNQ ILDSYSVILS
SDDaVVC%NS dYASqGl!An IkaFqqVLYY QNNVFMSEaK CWtEhDinnG PHEFCSQHTM LVKqddDdVY LPYP#PSRIL GAGCFVDDil KTDgtL$IER FVSLAIDAYP LtkHeN#EYa dVFrlYLaYI rKLh##Lgnq iLDmYSViLs

SARS-CoV-2
HCoV-OC43
Consensus

901
1050
NDNTSRYWEP EFYEAMYTPH TVLQAVGACV LCNSQTSLRC GACIRRPFLC CKCCYDHVIS TSHKLVLSVN PYVCNAPGCD VTDVTQLYLG GMSYYCKSHK PPISFPLCAN GQVFGLYKNT CVGSDNVTDF NAIATCDWTN AGDYILANTC
TCDGQKFTDE SFYKNMYLRS AVMQSVGACV VCSSQTSLRC GSCIRKPLLC CKCCYDHVMA TDHKYVLSVS PYVCNAPGCD VNDVTKLYLG GMSYYCEDHK PQYSFKLVMN GLVFGLYKQS CTGSPYIDDF NRIASCKWTD VDDYILANEC
nd#gqr%t#e eFYeaMYlrh aV$QaVGACV lCnSQTSLRC GaCIRrPlLC CKCCYDHVia TdHKlVLSVn PYVCNAPGCD VnDVTqLYLG GMSYYCedHK PqiSFkLcaN GqVFGLYK#s CtGSdn!dDF NaIAsCdWT# adDYILANeC

SARS-CoV-2
HCoV-OC43
Consensus

1051
1200
TERLKLFAAE TLKATEETFK LSYGIATVRE VLSDRELHLS WEVGKPRPPL NRNYVFTGYR VTKNSKVQIG EYTFEKGDYG DAVVYRGTTT YKLNVGDYFV LTSHTVMPLS TPTLVPQEHY VRITGLYPTL NISDEFSSNV ANYQKVGMQK
TERLKLFAAE TQKATEEAFK QSYASATIQE IVSERELILS WEIGKVKPPL NKNYVFTGYH FTKNGKTVLG EYVFDKSELT NGVYYRATTT YKLSVGDVFV LTSHSVANLS APTLVPQENY SSIR-FASVY SVLETFQNNV VNYQHIGMKR
TERLKLFAAE TqKATEEaFK qSYaiAT!rE !lS#RELhLS WE!GKprPPL NrNYVFTGYr fTKNgKtqiG EYtF#Kg#lg #aVyYRaTTT YKLnVGDyFV LTSHsVanLS aPTLVPQEnY srIr.laptl n!l#eFqnNV aNYQh!GMqr

SARS-CoV-2
HCoV-OC43
Consensus

1201
1350
YSTLQGPPGT GKSHFAIGLA LYYPSARIVY TACSHAAVDA LCEKALKYLP IDKCSRIIPA RARVECFDKF KVNSTLEQYV FCTVNALPET TADIVVFDEI SMATNYDLSV VNARLRAKHY VYIGDPAQLP APRTLLTKGT LEPEYFNSVC
YCTVQGPPGT GKSHLAIGLA VFYCTARVVY TAASHAAVDA LCEKAYKFLN INDCTRIVPA KVRVECYDKF KINDTTRKYV FTTINALPEM VTDIVVVDEV SMLTNYELSV INARIRAKHY VYIGDPAQLP APRVLLSKGT LEPKYFNTVT
YcTlQGPPGT GKSHlAIGLA l%YcsAR!VY TAaSHAAVDA LCEKAlK%Ln I#dCsRI!PA raRVEC%DKF K!NdTlrqYV FcT!NALPEm taDIVVfDE! SMaTNY#LSV !NARiRAKHY VYIGDPAQLP APRtLLsKGT LEPeYFNsVc

SARS-CoV-2
HCoV-OC43
Consensus

1351
1500
RLMKTIGPDM FLGTCRRCPA EIVDTVSALV YDNKLKAHKD KSAQCFKMFY KGVITHDVSS AINRPQIGVV REFLTRNPAW RKAVFISPYN SQNAVASKIL GLPTQTVDSS QGSEYDYVIF TQTTETAHSC NVNRFNVAIT RAKVGILCIM
KLMCCLGPDI FLGTCYRCPK EIVDTVSALV YENKLKAKNE SSSLCFKVYY KGVTTHESSS AVNMQQIYLI NKFLKANPLW HKAVFISPYN SQNFAAKRVL GLQTQTVDSA QGSEYDYVIY SQTAETAHSV NVNRFNVAIT RAKKGILCVM
rLMcciGPDi FLGTCrRCPa EIVDTVSALV Y#NKLKAhn# kSaqCFKm%Y KGViTH#sSS A!NrqQIgl! reFLkaNPaW rKAVFISPYN SQNaaAkr!L GLqTQTVDSa QGSEYDYVI% sQTaETAHSc NVNRFNVAIT RAKkGILC!M

SARS-CoV-2
HCoV-OC43
Consensus

1501
1650
SDRDLYDKLQ FTSLEIPRRN VAT-LQAENV TGLFKDCSKV ITGLHPTQAP THLSVDTKFK TEGLCVDIPG IPKD-MTYRR LISMMGFKMN YQVNGYPNMF ITREEAIRHV RAWIGFDVEG CHATREAVGT NLPLQLGFST GVNLVAVPTG
SNMQLFEALQ FTTLTLDKVP QAVETKVQCS TNLFKDCSKS YSGYHPAHAP SFLAVDDKYK ATGDLAVCLG IGDSAVTYSR LISLMGFKLD VTLDGYCKLF ITKEEAVKRV RAWVGFDAEG AHATRDSIGT NFPLQLGFST GIDFVVEATG
S#r#L%#aLQ FTsLeidrrn qAt.lqa#ns TnLFKDCSKs isGlHPaqAP shLaVDdK%K aeGdcadclG Igdd.mTYrR LIS$MGFK$# yql#GYcn$F ITrEEA!rrV RAW!GFDaEG aHATR#a!GT NlPLQLGFST G!#lVaeaTG

SARS-CoV-2
HCoV-OC43
Consensus

1651
1800
YVDTPNNTDF SRVSAKPPPG DQFKHLIPLM YKGLPWNVVR IKIVQMLSDT LKNLSDRVVF VLWAHGFELT SMKYFVKIGP ERTCCLCDRR ATCFSTASDT YACWHHSIGF DYVYNPFMID VQQWGFTGNL QSNHDLYCQV HGNAHVASCD
LFADRDGYSF KKAVAKAPPG EQFKHLIPLM TRGHRWDVVR PRIVQMFADH LIDLSDCVVL VTWAANFELT CLRYFAKVGR EISCNVCTKR ATVYNSRTGY YGCWRHSVTC DYLYNPLIVD IQQWGYIGSL SSNHDLYCSV HKGAHVASSD
lfadr#ntdF krasAKaPPG #QFKHLIPLM trGhrW#VVR irIVQMlaDh Li#LSDrVVl VlWAanFELT c$rYFaK!Gr ErsCnlCdrR ATc%nsasdt YaCWrHS!gc DYlYNPli!D !QQWG%iGnL qSNHDLYCqV HgnAHVAScD

SARS-CoV-2
HCoV-OC43
Consensus

1801
1950
AIMTRCLAVH ECFVKRVDWT IEYPIIGDEL KINAACRKVQ HMVVKAALLA DKFPVLHDIG NPKAIKCVPQ ADVEWKFYDA QPCSDKAYKI EELFYSYATH SDKFTDGVCL FWNCNVDRYP ANSIVCRFDT RVLSNLNLPG CDGGSLYVNK
AIMTRCLAVY DCFCNNINWN VEYPIISNEL SINTSCRVLQ RVILKAAMLC NRYTLCYDIG NPKAIACVK- -DFDFKFYDA QPI---VKSV KTLLYSFEAH KDSFKDGLCM FWNCNVDKYP PNAVVCRFDT RVLNNLNLPG CNGGSLYVNK
AIMTRCLAVh #CFcnr!#Wn !EYPIIg#EL kINaaCRklQ rm!lKAA$La #r%plchDIG NPKAIaCVk. .Df#fKFYDA QPc...akk! eeLlYS%aaH kDkFkDGlC$ FWNCNVDrYP aNa!VCRFDT RVLnNLNLPG C#GGSLYVNK

SARS-CoV-2
HCoV-OC43
Consensus

1951
2100
HAFHTPAFDK SAFVNLKQLP FFYYSDSPCE SHGKQVVSDI DYVPLKSATC ITRCNLGGAV CRHHANEYRL YLDAYNMMIS AGFSLWVYKQ FDTYNLWNTF TRLQSLENVA FNVVNKGHFD GQQGEVPVSI INNTVYTKVD GVDVELFENK
HAFHTKPFAR AAFEHLKPMP FFYYSDTPCV YMDGMDAKQV DYVPLKSATC ITRCNLGGAV CLKHAEEYRE YLESYNTATT AGFTFWVYKT FDFYNLWNTF TKLQSLENVV YNLVKTGHYT GQAGEMPCAI INDKVVAKID KEDVVIFINN
HAFHTkaFar aAFenLKq$P FFYYSDsPCe shdgqdak#! DYVPLKSATC ITRCNLGGAV CrhHA#EYRe YL#aYNmais AGFslWVYKq FDfYNLWNTF TrLQSLENVa %NlVnkGH%d GQaGEmPcaI IN#kVyaK!D geDVeiFeNn

SARS-CoV-2
HCoV-OC43
Consensus

2101
2250
TTLPVNVAFE LWAKRNIKPV PEVKILNNLG VDIAANTVIW DYKRDAPAHI STIGVCSMTD IAKKPTETIC APLTVFFDGR VDGQVDLFRN ARNGVLITEG SVKGLQPSVG PKQASLNGVT L--IGE---- ---AVKTQ-- ---FNYYKKV
TTYPTNVAVE LFAKRSVRHH PELKLFRNLN IDVCWKHVIW DYARESIFCS NTYGVCMYTD LK------FI DKLNVLFDGR DNGALEAFKR SNNGVYISTT KVKSLSMIRG PPRAELNGVV VDKVGDTDCV FYFAVRKEGQ DVIFSQFDSL
TTlPtNVAfE LfAKRn!rhh PElKilrNLn !D!aanhVIW DYaR#aiaci nTiGVCmmTD ia......ic akLnVlFDGR d#Gal#aFrr arNGVlIseg kVKgLqmirG PkrAeLNGVt l..!G#.... ...AVrk#.. ...Fnq%dkl

SARS-CoV-2
HCoV-OC43
Consensus

2251
2400
DGVVQQLPE- ---------- ---------- TYFTQSRNLQ EFKPRSQMEI DFLELAMDEF IERYKLEGYA FEHIVYGDFS HSQLGGLHLL IGLAKRFKES PFELEDFIPM DSTVKNYFIT DAQTGSSKCV CSVIDLLLDD FVEIIKSQDL
GVSSNQSPQG NLGSNGKPGN VGGNDALSIS TIFTQSRVIS SFTCRTDMEK DFIALDQDVF IQKYGLEDYA FEHIVYGNFN QKIIGGLHLL IGLYRRQQTS NLVVQEFVSY DSSIHSYFIT DEKSGGSKSV CTVIDILLDD FVALVKSLNL
dgss#QlP#. .......... .......... TiFTQSRniq eFkcRs#MEi DFiaLaqDeF I#rYgLEdYA FEHIVYG#Fn qkqiGGLHLL IGLarRqqeS nlel##F!pm DSs!hnYFIT DaqsGgSKcV CsVIDiLLDD FVai!KSq#L

SARS-CoV-2
HCoV-OC43
Consensus

2401
2550
SVVSKVVKVT IDYTEISFML WCKDGHVETF YPKLQSSQAW QPGVAMPNLY KMQRMLLEKC DLQNYGDSAT LPKGIMMNVA KYTQLCQYLN TLTLAVPYNM RVIHFGAGSD KGVAPGTAVL RQWLPTGTLL VDSDLNDFVS DADSTLIGDC
NCVSKVVNVN VDFKDFQFML WCNDEKVMTF YPRLQAASDW KPGYSMPVLY KYLNSPMERV SLWNYGKPVT LPTGCMMNVA KYTQLCQYLN TTTLAVPVNM RVLHLGAGSE KGVAPGSAVL RQWLPAGTIL VDNDLYPFVS DSVATYFGDC
ncVSKVVnVn !D%k#iqFML WCnDehVeTF YPrLQaaqaW qPGyaMPnLY Kmqrml$Erc dLqNYGdpaT LPkGcMMNVA KYTQLCQYLN TlTLAVPyNM RViHlGAGS# KGVAPGsAVL RQWLPaGTiL VDnDLndFVS DadaTliGDC

